Cancer Research and Treatment

Volume 46(3); July 2014

Review Article

Regulation and Role of EZH2 in Cancer: Hirohito Yamaguchi, Mien-Chie Hung; Cancer Res Treat. 2014;46(3):209-222. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.209

Polycomb repressive complex 2 (PRC2) is the epigenetic regulator that induces histone H3 lysine 27 methylation (H3K27me3) and silences specific gene transcription. Enhancer of zeste homolog 2 (EZH2) is an enzymatic subunit of PRC2, and evidence shows that EZH2 plays an essential role in cancer initiation, development, progression, metastasis, and drug resistance. EZH2 expression is indeed regulated by various oncogenic transcription factors, tumor suppressor miRNAs, and cancer-associated non-coding RNA. EZH2 activity is also controlled by post-translational modifications, which are deregulated in cancer. The canonical role of EZH2 is gene silencing through H3K27me3, but accumulating evidence shows that EZH2 methlyates substrates other than histone and has methylase-independent functions. These non-canonical functions of EZH2 are shown to play a role in cancer progression. In this review, we summarize current information on the regulation and roles of EZH2 in cancer. We also discuss various therapeutic approaches to targeting EZH2.

Citations

Citations to this article as recorded by

Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2)
Xin Xu, Jia Chen, Guan Wang, Xiaojuan Zhang, Qiang Li, Xiaobo Zhou, Fengying Guo, Min Li
Bioorganic & Medicinal Chemistry Letters.2024; 97: 129558. CrossRef
Development of a Cost-Efficient Process Toward a Key Synthetic Intermediate of the EZH2 Inhibitor PF-06821497
Christopher P. Ashcroft, Alexander M. Berne, Florian Blasberg, Kelly Catlin, Michael R. Collins, Doug J. Critcher, Jean-Nicolas Desrosiers, Adam Goetz, Cheryl Hayward, Ricky A. Jones, Michael J. Karmilowicz, Nandell Keene, Carlos A. Martinez, Sebastien Mo
Organic Process Research & Development.2024; 28(6): 2260. CrossRef
MicroRNAs and long non-coding RNAs during transcriptional regulation and latency of HIV and HTLV
Sergio P. Alpuche-Lazcano, Robert J. Scarborough, Anne Gatignol
Retrovirology.2024;[Epub] CrossRef
Nuclear Biophysical Changes during Human Melanoma Plasticity
Maria Chiara Lionetti, Maria Rita Fumagalli, Caterina A.M. La Porta
Cells Tissues Organs.2024; 213(2): 120. CrossRef
The Role of H3K27me3-Mediated Th17 Differentiation in Ankylosing Spondylitis
Yuening Chen, Wanlin Liu, Xiaohan Xu, Hongying Zhen, Bo Pang, Zhe Zhao, Yanan Zhao, Hongxiao Liu
Inflammation.2024; 47(5): 1685. CrossRef
O‐GlcNAc regulates anti‐fibrotic genes in lung fibroblasts through EZH2
Qiuming P. Wu, Shia Vang, Jennifer Q. Zhou, Stefanie Krick, Jarrod W. Barnes, Yan Y. Sanders
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
A Case of SMARCB1-Deficient Sinonasal Carcinoma With Clear Cell Morphology
Tomoko Tamaki, Kyonosuke Teruya, Hitoshi Hirakawa, Mariko Tomita, Naoki Wada
Cureus.2024;[Epub] CrossRef
Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST
Dayong Zheng, Yan Zhang, Sukjin Yang, Ning Su, Michael Bakhoum, Guoliang Zhang, Samira Naderinezhad, Zhengmei Mao, Zheng Wang, Ting Zhou, Wenliang Li
Cell Death Discovery.2024;[Epub] CrossRef
EZH2‐associated tumor malignancy: A prominent target for cancer treatment
Maryam Sabour‐Takanlou, Leila Sabour‐Takanlou, Cigir Biray‐Avci
Clinical Genetics.2024; 106(4): 377. CrossRef
Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases
Eswaran Devarajan, R. Eric Davis, Hannah C. Beird, Wei-Lien Wang, V. Behrana Jensen, Arumugam Jayakumar, Cheuk Hong Leung, Heather Y. Lin, Chia-Chin Wu, Stephanie A. Ihezie, Jen-Wei Tsai, P. Andrew Futreal, Valerae O. Lewis
Discover Oncology.2024;[Epub] CrossRef
Bisphenol S (BPS) induces glioblastoma progression via regulation of EZH2-mediated PI3K/AKT/mTOR pathway in U87-MG cells
Moon Yi Ko, Heejin Park, Younhee Kim, Euijun Min, Sin-Woo Cha, Byoung-Seok Lee, Sung-Ae Hyun, Minhan Ka
Toxicology.2024; 507: 153898. CrossRef
SWI/SNF-Related Matrix-Associated Actin-Dependent Regulator of Chromatin Subfamily B Member 1 (SMARCB1)-Deficient Tumor in the Parapharyngeal Space: A Case Report
Seiichiro Kamimura, Eiji Kondo, Takahiro Azuma, Go Sato, Yoshiaki Kitamura
Cureus.2024;[Epub] CrossRef
H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications
Giuseppe Angelico, Manuel Mazzucchelli, Giulio Attanasio, Giordana Tinnirello, Jessica Farina, Magda Zanelli, Andrea Palicelli, Alessandra Bisagni, Giuseppe Maria Vincenzo Barbagallo, Francesco Certo, Maurizio Zizzo, Nektarios Koufopoulos, Gaetano Magro,
Cancers.2024; 16(20): 3451. CrossRef
A study of the diagnostic and prognostic role of enhancer of zeste homolog 2 and BRCA1-associated protein 1 expression in different prostatic lesions (an immunohistochemical study)
Samah I. Saleh, Amira E. Soliman, Mona A. Aboelkheir
Egyptian Journal of Pathology.2024; 44(1): 48. CrossRef
EZH2 Activates HTLV‐1 bZIP Factor‐Mediated TGF‐β Signaling in Adult T‐Cell Leukemia
Xu Zhang, Kaining Yi, Bingbing Wang, Kaifei Chu, Jie Liu, Jie Zhang, Jiaqi Fang, Tiejun Zhao
Journal of Medical Virology.2024;[Epub] CrossRef
CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy
Yinying Pu, Wencheng Wu, Huijing Xiang, Yu Chen, Huixiong Xu
Nano Today.2023; 48: 101734. CrossRef
EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression
Zong-Shin Lin, Chiao-Chen Chung, Yu-Chia Liu, Chu-Han Chang, Hui-Chia Liu, Yung-Yi Liang, Teng-Le Huang, Tsung-Ming Chen, Che-Hsin Lee, Chih-Hsin Tang, Mien-Chie Hung, Ya-Huey Chen
eLife.2023;[Epub] CrossRef
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
Husheng Mei, Hong Wu, Jing Yang, Bin Zhou, Aoli Wang, Chen Hu, Shuang Qi, Zongru Jiang, Fengming Zou, Beilei Wang, Feiyang Liu, Yongfei Chen, Wenchao Wang, Jing Liu, Qingsong Liu
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef
SMARCB1(INI-1)-Deficient Sinonasal Carcinoma: An Evolving Entity
Sei Y. Chung, Parker Kenee, Tanner Mitton, Ashleigh Halderman
Journal of Neurological Surgery Reports.2023; 84(01): e1. CrossRef
Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
Anne Uebel, Stefanie Kewitz-Hempel, Edith Willscher, Kathleen Gebhardt, Cord Sunderkötter, Dennis Gerloff
International Journal of Molecular Sciences.2023; 24(3): 1963. CrossRef
miRNA let-7a inhibits invasion, migration, anchorage-independent growth by suppressing EZH2 and promotes mesenchymal to epithelial transition in MDAMB-231
Nibedita Patel, Koteswara Rao Garikapati, Venkata Krishna Kanth Makani, Shreya Pal, Namratha Vangara, Manika Pal Bhadra
Gene Reports.2023; 31: 101752. CrossRef
Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1
Seong Hwi Hong, Hyun Ji Hwang, Da Hyeon Son, Eun Song Kim, Sung Yul Park, Young Eun Yoon
FEBS Open Bio.2023; 13(4): 724. CrossRef
Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells
Y. Sbirkov, T. Schenk, C. Kwok, S. Stengel, R. Brown, G. Brown, L. Chesler, A. Zelent, M. J. Fuchter, K. Petrie
Frontiers in Cell and Developmental Biology.2023;[Epub] CrossRef
Dual role of enhancer of zeste homolog 2 in the regulation of ultraviolet radiation-induced matrix metalloproteinase-1 and type I procollagen expression in human dermal fibroblasts
Min-Kyoung Kim, Hye Sun Shin, Mi Hee Shin, Haesoo Kim, Dong Hun Lee, Jin Ho Chung
Matrix Biology.2023; 119: 112. CrossRef
A patent review of EZH2 inhibitors from 2017 and beyond
Guoquan Wan, Huan Feng, Chang Su, Yongxia Zhu, Lidan Zhang, Qiangsheng Zhang, Luoting Yu
Expert Opinion on Therapeutic Patents.2023; 33(4): 293. CrossRef
Epigenetic effects of herbal medicine
Yu-Yao Wu, Yan-Ming Xu, Andy T. Y. Lau
Clinical Epigenetics.2023;[Epub] CrossRef
Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2
Donghee Kim, Ka-Yun Ban, Geon-Ho Lee, Hee-Sook Jun
International Journal of Molecular Sciences.2023; 24(12): 9968. CrossRef
SMARCB1‐deficient basal cell carcinoma of the prostate controlled using radiation therapy
Shunta Makabe, Tomoyuki Koguchi, Kanako Matsuoka, Seiji Hoshi, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Motohide Uemura, Yoshiyuki Kojima
IJU Case Reports.2023; 6(4): 248. CrossRef
JARID2 and EZH2, the eminent epigenetic drivers in human cancer
Bhuvanadas Sreeshma, Arikketh Devi
Gene.2023; 879: 147584. CrossRef
Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy
Xinye Chen, Cheng Wang, Dehua Lu, Heng Luo, Shang Li, Fucheng Yin, Zhongwen Luo, Ningjie Cui, Lingyi Kong, Xiaobing Wang
Bioorganic & Medicinal Chemistry.2023; 91: 117386. CrossRef
Review: Targeting EZH2 in neuroblastoma
Jinhui Gao, Claire Fosbrook, Jane Gibson, Timothy J. Underwood, Juliet C. Gray, Zoë S. Walters
Cancer Treatment Reviews.2023; 119: 102600. CrossRef
Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures
Julian Aldana, Miranda L. Gardner, Michael A. Freitas
International Journal of Molecular Sciences.2023; 24(14): 11378. CrossRef
The Role of EZH2 in Ocular Diseases: A Narrative Review
Yu Peng, Christine HT Bui, Xiu J Zhang, Jian S Chen, Clement C Tham, Wai K Chu, Li J Chen, Chi P Pang, Jason C Yam
Epigenomics.2023; 15(9): 557. CrossRef
Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors
Cinzia Lanzi, Noemi Arrighetti, Sandro Pasquali, Giuliana Cassinelli
Biochemical Pharmacology.2023; 215: 115727. CrossRef
EZH2-mediated epigenetic silencing of tumor-suppressive let-7c/miR-99a cluster by hepatitis B virus X antigen enhances hepatocellular carcinoma progression and metastasis
Chen-Shiou Wu, Yi-Chung Chien, Chia‐Jui Yen, Jia-Yan Wu, Li-Yuan Bai, Yung-Luen Yu
Cancer Cell International.2023;[Epub] CrossRef
SUZ12 inhibition attenuates cell proliferation of glioblastoma via post-translational regulation of CDKN1B
Sojin Kim, Sungsin Jo, Sun Ha Paek, Sang Soo Kang, Heekyoung Chung
Genes & Genomics.2023; 45(12): 1623. CrossRef
Non-Coding RNA in Cholangiocarcinoma: An Update
Jiehan Li, Haolin Bao, Ziyue Huang, Zixin Liang, Ning Lin, Chunjie Ni, Yi Xu
Frontiers in Bioscience-Landmark.2023;[Epub] CrossRef
Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses
Xue Shui, Rong Xu, Caiqin Zhang, Han Meng, Jumei Zhao, Changhong Shi
Laboratory Investigation.2022; 102(4): 332. CrossRef
MicroRNA-217: a therapeutic and diagnostic tumor marker
Amir Abbas Hamidi, Malihe Zangoue, Daniel Kashani, Amir Sadra Zangouei, Hamid Reza Rahimi, Mohammad Reza Abbaszadegan, Meysam Moghbeli
Expert Review of Molecular Diagnostics.2022; 22(1): 61. CrossRef
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2
Jing Yang, Ellen L. Weisberg, Shuang Qi, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S. Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara
Leukemia.2022; 36(4): 1048. CrossRef
Mechanisms of Polycomb group protein function in cancer
Victoria Parreno, Anne-Marie Martinez, Giacomo Cavalli
Cell Research.2022; 32(3): 231. CrossRef
Clinical Diagnosis and Treatment Analyses on SMARCB1 (Integrase Interactor 1)–Deficient Sinonasal Carcinoma: Case Series with Systematic Review of the Literature
Ru Wang, Lingwa Wang, Jugao Fang, Qi Zhong, Lizhen Hou, Hongzhi Ma, Ling Feng, Shizhi He, Chengshuo Wang, Luo Zhang
World Neurosurgery.2022; 161: e229. CrossRef
EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis
Susan Fineberg, Xuejun Tian, Della Makower, Malini Harigopal, Yungtai Lo
Applied Immunohistochemistry & Molecular Morphology.2022; 30(3): 157. CrossRef
Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma
Matthew L. Hedberg, Corbett T. Berry, Ata S. Moshiri, Yan Xiang, Christopher J. Yeh, Cem Attilasoy, Brian C. Capell, John T. Seykora
International Journal of Molecular Sciences.2022; 23(7): 3478. CrossRef
Identification of SET/EED Dual Binders As Innovative PRC2 Inhibitors
Raffaella Catalano, Annalisa Maruca, Roberta Rocca, Pierfrancesco Tassone, Giulia Panzarella, Giosuè Costa, Francesco Ortuso, Stefano Alcaro
Future Medicinal Chemistry.2022; 14(9): 609. CrossRef
METTL3 Accelerates Breast Cancer Progression via Regulating EZH2 m6A Modification
Shaojun Hu, Yang Song, Yu Zhou, Yu Jiao, Guopeng Li, Deepak Kumar Jain
Journal of Healthcare Engineering.2022; 2022: 1. CrossRef
IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2
Florian Sperling, Danny Misiak, Stefan Hüttelmaier, Patrick Michl, Heidi Griesmann
Cancers.2022; 14(9): 2121. CrossRef
KDM2B mediates the Wnt/β-catenin pathway through transcriptional activation of PKMYT1 via microRNA-let-7b-5p/EZH2 to affect the development of non-small cell lung cancer
Xuedong Zhang, Zhongbo Yin, Chuanyi Li, Lishen Nie, Keyan Chen
Experimental Cell Research.2022; 417(2): 113208. CrossRef
Loss of H3K27 Trimethylation Promotes Radiotherapy Resistance in Medulloblastoma and Induces an Actionable Vulnerability to BET Inhibition
Nishanth Gabriel, Kumaresh Balaji, Kay Jayachandran, Matthew Inkman, Jin Zhang, Sonika Dahiya, Michael Goldstein
Cancer Research.2022; 82(10): 2019. CrossRef
Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
Rachel Abbotts, Anna J. Dellomo, Feyruz V. Rassool
Cancers.2022; 14(11): 2640. CrossRef
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer
Daniel Sanghoon Shin, Kevin Park, Edward Garon, Steven Dubinett
Seminars in Oncology.2022; 49(3-4): 306. CrossRef
SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma: A Systematic Review and Pooled Analysis of Treatment Outcomes
Victor Ho-Fun Lee, Raymond King-Yin Tsang, Anthony Wing Ip Lo, Sum-Yin Chan, Joseph Chun-Kit Chung, Chi-Chung Tong, To-Wai Leung, Dora Lai-Wan Kwong
Cancers.2022; 14(13): 3285. CrossRef
Degradable polyprodrugs: design and therapeutic efficiency
Farzad Seidi, Yajie Zhong, Huining Xiao, Yongcan Jin, Daniel Crespy
Chemical Society Reviews.2022; 51(15): 6652. CrossRef
PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer
Shoshana Sedley, Jeetendra Kumar Nag, Tatyana Rudina, Rachel Bar-Shavit
International Journal of Molecular Sciences.2022; 23(15): 8758. CrossRef
Insight into Thermodynamic and Kinetic Profiles in Small-Molecule Optimization
Wei Liu, Jingsheng Jiang, Yating Lin, Qidong You, Lei Wang
Journal of Medicinal Chemistry.2022; 65(16): 10809. CrossRef
EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response
Yujun Gan, Yungtai Lo, Della Makower, Celina Kleer, Jinyu Lu, Susan Fineberg
Applied Immunohistochemistry & Molecular Morphology.2022; 30(9): 614. CrossRef
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies
Dehua Lu, Cheng Wang, Lailiang Qu, Fucheng Yin, Shang Li, Heng Luo, Yonglei Zhang, Xingchen Liu, Xinye Chen, Zhongwen Luo, Ningjie Cui, Lingyi Kong, Xiaobing Wang
Journal of Medicinal Chemistry.2022; 65(19): 12838. CrossRef
EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
Ivana Samaržija, Marko Tomljanović, Renata Novak Kujundžić, Koraljka Gall Trošelj
Cancers.2022; 14(19): 4761. CrossRef
The role of transcription factors in the acquisition of the four latest proposed hallmarks of cancer and corresponding enabling characteristics
Maria P. Morgan, Ellen Finnegan, Sudipto Das
Seminars in Cancer Biology.2022; 86: 1203. CrossRef
EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes
Jinqiang Zhang, Weina Chen, Wenbo Ma, Chang Han, Kyoungsub Song, Hyunjoo Kwon, Tong Wu
The American Journal of Pathology.2022; 192(12): 1712. CrossRef
Distinct binding pattern of EZH2 and JARID2 on RNAs and DNAs in hepatocellular carcinoma development
Zhili Wen, Ke He, Meixiao Zhan, Yong Li, Fei Liu, Xu He, Yanli Wei, Wei Zhao, Yu Zhang, Yaqiang Xue, Yong Xia, Fenfen Wang, Zhenglin Xia, Yongjie Xin, Yeye Wu, Xiaopeng Duan, Jing Xiao, Feng Shen, Yuliang Feng, Guoan Xiang, Ligong Lu
Frontiers in Oncology.2022;[Epub] CrossRef
Dynamic‐shared Pharmacophore Approach as Tool to Design New Allosteric PRC2 Inhibitors, Targeting EED Binding Pocket
Jessica Lombino, Maria Rita Gulotta, Giada De Simone, Nedra Mekni, Maria De Rosa, Daniela Carbone, Barbara Parrino, Stella Maria Cascioferro, Patrizia Diana, Alessandro Padova, Ugo Perricone
Molecular Informatics.2021;[Epub] CrossRef
Chain-shattering Pt(IV)-backboned polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic cancer therapy
Qingfei Zhang, Gaizhen Kuang, Shasha He, Sha Liu, Hongtong Lu, Xiaoyuan Li, Dongfang Zhou, Yubin Huang
Nano Research.2021; 14(3): 601. CrossRef
Elevated EZH2 in ischemic heart disease epigenetically mediates suppression of NaV1.5 expression
Limei Zhao, Tao You, Yan Lu, Shin Lin, Faqian Li, Haodong Xu
Journal of Molecular and Cellular Cardiology.2021; 153: 95. CrossRef
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Luciana Mosca, Andrea Ilari, Francesco Fazi, Yehuda G. Assaraf, Gianni Colotti
Drug Resistance Updates.2021; 54: 100742. CrossRef
MicroRNAs Involved in Inflammatory Breast Cancer: Oncogene and Tumor Suppressors with Possible Targets
Zohreh Rezaei, Farzad Sadri
DNA and Cell Biology.2021; 40(3): 499. CrossRef
Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation
Karolina Pyziak, Agnieszka Sroka‐Porada, Tomasz Rzymski, Józef Dulak, Agnieszka Łoboda
Drug Development Research.2021; 82(6): 730. CrossRef
The noncanonical role of EZH2 in cancer
Jinhua Huang, Hongwei Gou, Jia Yao, Kaining Yi, Zhigang Jin, Masao Matsuoka, Tiejun Zhao
Cancer Science.2021; 112(4): 1376. CrossRef
RePhine: An Integrative Method for Identification of Drug Response-Related Transcriptional Regulators
Xujun Wang, Zhengtao Zhang, Wenyi Qin, Shiyi Liu, Cong Liu, Georgi Z. Genchev, Lijian Hui, Hongyu Zhao, Hui Lu
Genomics, Proteomics & Bioinformatics.2021; 19(4): 534. CrossRef
Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study
Sarah Adel Hakim, Hoda Hassan Abou Gabal
Pathology and Oncology Research.2021;[Epub] CrossRef
Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma
Changhee Park, Tae Min Kim, Jeong Mo Bae, Hongseok Yun, Jin Wook Kim, Seung Hong Choi, Soon-Tae Lee, Joo Ho Lee, Sung-Hye Park, Chul-Kee Park
Cancer Research and Treatment.2021; 53(2): 389. CrossRef
Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer
Alba Loras, Cristina Segovia, José Luis Ruiz-Cerdá
Cancers.2021; 13(11): 2719. CrossRef
The Biological Function, Mechanism, and Clinical Significance of m6A RNA Modifications in Head and Neck Carcinoma: A Systematic Review
Feng-Yang Jing, Li-Ming Zhou, Yu-Jie Ning, Xiao-Juan Wang, You-Ming Zhu
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
Yong Jun Lee, Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim
Molecules and Cells.2021; 44(5): 363. CrossRef
Horizontal transfer of the stemness-related markers EZH2 and GLI1 by neuroblastoma-derived extracellular vesicles in stromal cells
Aranzazu Villasante, Amandine Godier-Furnemont, Alberto Hernandez-Barranco, Johanne Le Coq, Jasminka Boskovic, Hector Peinado, Jaume Mora, Josep Samitier, Gordana Vunjak-Novakovic
Translational Research.2021; 237: 82. CrossRef
PBDEs affect inflammatory and oncosuppressive mechanisms via the EZH2 methyltransferase in airway epithelial cells
Giulia Anzalone, Monica Moscato, Angela Marina Montalbano, Giusy Daniela Albano, Rosalia Gagliardo, Roberto Marchese, Alberto Fucarino, Chiara Lo Nigro, Gaspare Drago, Mirella Profita
Life Sciences.2021; 282: 119827. CrossRef
Overexpression of miR-378 Alleviates Chronic Sciatic Nerve Injury by Targeting EZH2
Pengfei Gao, Xin Zeng, Lin Zhang, Long Wang, Lu-Lu Shen, Ya-Yun Hou, Fang Zhou, Xianlong Zhang
Neurochemical Research.2021; 46(12): 3213. CrossRef
Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells
Nobuyo Kondo, Yoshiko Nagano, Atsuhiko Hasegawa, Miku Ishizawa, Kuniko Katagiri, Takeru Yoneda, Takao Masuda, Mari Kannagi
Biochemical and Biophysical Research Communications.2021; 574: 104. CrossRef
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas
Bin Zhou, Xiaofei Liang, Husheng Mei, Shuang Qi, Zongru Jiang, Aoli Wang, Fengming Zou, Qingwang Liu, Juan Liu, Wenliang Wang, Chen Hu, Yongfei Chen, Zuowei Wang, Beilei Wang, Li Wang, Jing Liu, Qingsong Liu
Journal of Medicinal Chemistry.2021; 64(20): 15170. CrossRef
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
Yuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, Shuhei Koide, Ola Rizq, Kazumasa Aoyama, Junjie Ao, Tatsuya Kaneko, Hiroaki Kanzaki, Kengo Kanayama, Takahiro Maeda, Tomoko Saito, Ryo Nakagawa, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Sadahis
Scientific Reports.2021;[Epub] CrossRef
Histone Demethylase UTX/KDM6A Regulates Glioblastoma Progression Through Modulating the Tumor Microenvironment
Yan Luan, Yingfei Liu, Jingwen Xue, Ke Wang, Kaige Ma, Xinlin Chen, Zhichao Zhang, Yong Liu
SSRN Electronic Journal .2021;[Epub] CrossRef
LncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating EZH2 expression
Zhao-Yang Yang, Fang Yang, Ying-Li Zhang, Bao Liu, Meng Wang, Xuan Hong, Yan Yu, Yao-Hui Zhou, Hai Zeng
Cancer Biomarkers.2020; 18(1): 95. CrossRef
Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF4E/PUMA pathway
Huanan Wang, Yeying Liu, Jie Ding, Yuan Huang, Jing Liu, Nannan Liu, Yue Ao, Yi Hong, Lefeng Wang, Lingling Zhang, Jiangang Wang, Yingjie Zhang
Cancer Gene Therapy.2020; 27(6): 448. CrossRef
Utility of histone H3K27me3 and H4K20me as diagnostic indicators of melanoma
Lauren E. Davis, Sara C. Shalin, Alan J. Tackett
Melanoma Research.2020; 30(2): 159. CrossRef
Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis
Yingfeng Shi, Min Tao, Yi Wang, Xiujuan Zang, Xiaoyan Ma, Andong Qiu, Shougang Zhuang, Na Liu
The Journal of Pathology.2020; 250(1): 79. CrossRef
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
Shira Yomtoubian, Sharrell B. Lee, Akanksha Verma, Franco Izzo, Geoffrey Markowitz, Hyejin Choi, Leandro Cerchietti, Linda Vahdat, Kristy A. Brown, Eleni Andreopoulou, Olivier Elemento, Jenny Chang, Giorgio Inghirami, Dingcheng Gao, Seongho Ryu, Vivek Mit
Cell Reports.2020; 30(3): 755. CrossRef
HOXC10 promotes cell migration, invasion, and tumor growth in gastric carcinoma cells through upregulating proinflammatory cytokines
Jingzhang Li, Gangling Tong, Cheng Huang, Yunsheng Luo, Shubin Wang, Ying Zhang, Boran Cheng, Zhihong Zhang, Xuan Wu, Qiumei Liu, Min Li, Laiqing Li, Bingqiang Ni
Journal of Cellular Physiology.2020; 235(4): 3579. CrossRef
A TGF-β-MTA1-SOX4-EZH2 signaling axis drives epithelial–mesenchymal transition in tumor metastasis
Lina Li, Jian Liu, Hongsheng Xue, Chunxiao Li, Qun Liu, Yantong Zhou, Ting Wang, Haijuan Wang, Haili Qian, Tao Wen
Oncogene.2020; 39(10): 2125. CrossRef
Network-Based Genetic Profiling Reveals Cellular Pathway Differences Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma
Md. Ali Hossain, Tania Akter Asa, Md. Mijanur Rahman, Shahadat Uddin, Ahmed A. Moustafa, Julian M. W. Quinn, Mohammad Ali Moni
International Journal of Environmental Research and Public Health.2020; 17(4): 1373. CrossRef
Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time
Avinash Khanna, Alexandre Côté, Shilpi Arora, Ludivine Moine, Victor S. Gehling, Jehrod Brenneman, Nico Cantone, Jacob I. Stuckey, Shruti Apte, Ashwin Ramakrishnan, Kamil Bruderek, William D. Bradley, James E. Audia, Richard T. Cummings, Robert J. Sims, P
ACS Medicinal Chemistry Letters.2020; 11(6): 1205. CrossRef
Cancer Stem Cell Plasticity – A Deadly Deal
Archana P. Thankamony, Kritika Saxena, Reshma Murali, Mohit Kumar Jolly, Radhika Nair
Frontiers in Molecular Biosciences.2020;[Epub] CrossRef
Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model
Chidimma Agatha Akpa, Karsten Kleo, Elisabeth Oker, Nancy Tomaszewski, Clemens Messerschmidt, Cristina López, Rabea Wagener, Kathrin Oehl-Huber, Katja Dettmer, Anne Schoeler, Dido Lenze, Peter J. Oefner, Dieter Beule, Reiner Siebert, David Capper, Lora Di
BMC Cancer.2020;[Epub] CrossRef
Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression
Yang Yu, Qiaoyu Chen, Xunlei Zhang, Jian Yang, Kaibo Lin, Congfei Ji, Aibing Xu, Lei Yang, Lin Miao
Cancer Science.2020; 111(7): 2297. CrossRef
CAMK2A supported tumor initiating cells of lung adenocarcinoma by upregulating SOX2 through EZH2 phosphorylation
Si-Qi Wang, Jing Liu, Jing Qin, Yun Zhu, Vicky Pui-Chi Tin, Judy Wai Ping Yam, Maria Pik Wong, Zhi-Jie Xiao
Cell Death & Disease.2020;[Epub] CrossRef
INI-1 (SMARCB1)–Deficient Undifferentiated Sinonasal Carcinoma: Novel Paradigm of Molecular Testing in the Diagnosis and Management of Sinonasal Malignancies
Khvaramze Shaverdashvili, Elham Azimi-Nekoo, Perry Cohen, Nadeem Akbar, Thomas J. Ow, Balazs Halmos, Enrico Castellucci
The Oncologist.2020; 25(9): 738. CrossRef
Genomic profiling in renal cell carcinoma
Nazli Dizman, Errol J. Philip, Sumanta K. Pal
Nature Reviews Nephrology.2020; 16(8): 435. CrossRef
The Roles of the Histone Protein Modifier EZH2 in the Uterus and Placenta
Ana M. Mesa, Cheryl S. Rosenfeld, Geetu Tuteja, Theresa I. Medrano, Paul S. Cooke
Epigenomes.2020; 4(3): 20. CrossRef
FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway
Cheng-Cao Sun, Wei Zhu, Shu-Jun Li, Wei Hu, Jian Zhang, Yue Zhuo, Han Zhang, Juan Wang, Yu Zhang, Shao-Xin Huang, Qi-Qiang He, De-Jia Li
Genome Medicine.2020;[Epub] CrossRef
The long non‐coding RNA SNHG1 promotes bladder cancer progression by interacting with miR‐143‐3p and EZH2
Wei Xiang, Lei Lyu, Tao Huang, Fuxin Zheng, Jingdong Yuan, Chuanhua Zhang, Guosong Jiang
Journal of Cellular and Molecular Medicine.2020; 24(20): 11858. CrossRef
Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India
Asad Ur Rehman, Mohammad Askandar Iqbal, Real Sumayya Abdul Sattar, Snigdha Saikia, Mohammad Kashif, Wasif Mohammad Ali, Subhash Medhi, Sundeep Singh Saluja, Syed Akhtar Husain
Cancer Cell International.2020;[Epub] CrossRef
MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
Birlipta Pattanayak, Iris Garrido-Cano, Anna Adam-Artigues, Eduardo Tormo, Begoña Pineda, Paula Cabello, Elisa Alonso, Begoña Bermejo, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Federico Rojo, Octavio Burgués, Juan Miguel Cejalvo
Frontiers in Oncology.2020;[Epub] CrossRef
Inhibition of EZH2 via the STAT3/HOTAIR signalling axis contributes to cell cycle arrest and apoptosis induced by polyphyllin I in human non-small cell lung cancer cells
Hok Shing Li, Yao Xu
Steroids.2020; 164: 108729. CrossRef
EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis
Xiaowen Guan, Houliang Deng, Un Lam Choi, Zhengfeng Li, Yiqi Yang, Jianming Zeng, Yunze Liu, Xuanjun Zhang, Gang Li
Oncogene.2020; 39(48): 7127. CrossRef
RETRACTED: Exosome-Delivered LncHEIH Promotes Gastric Cancer Progression by Upregulating EZH2 and Stimulating Methylation of the GSDME Promoter
Yan Lu, Kaiqing Hou, Mengsen Li, Xiaobin Wu, Shaochun Yuan
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness
Ralf Hass, Juliane von der Ohe, Hendrik Ungefroren
Cancers.2020; 12(12): 3716. CrossRef
The EZH2–PHACTR2–AS1–Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer
Wenhui Chu, Xi Zhang, Lihua Qi, Yenan Fu, Peng Wang, Wei Zhao, Juan Du, Jing Zhang, Jun Zhan, Yunling Wang, Wei-Guo Zhu, Yu Yu, Hongquan Zhang
Cancer Research.2020; 80(13): 2737. CrossRef
Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer
Yifan Kong, Yanquan Zhang, Fengyi Mao, Zhuangzhuang Zhang, Zhiguo Li, Ruixin Wang, Jinghui Liu, Xiaoqi Liu
Molecular Cancer Therapeutics.2020; 19(12): 2490. CrossRef
Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis
Jumei Liu, Li Liang, Sixia Huang, Lin Nong, Dong Li, Bo Zhang, Ting Li
Human Pathology.2019; 83: 166. CrossRef
Retracted: Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57KIP2 and involving in p‐p38 MAPK and NF‐κB pathways
Enqi Qiao, Daobao Chen, Qinglin Li, Weiliang Feng, Xingfei Yu, Xiping Zhang, Liang Xia, Ju Jin, Hongjian Yang
Journal of Cellular Biochemistry.2019; 120(3): 3978. CrossRef
Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells
Fei Jiang, Yuan Li, Lu Si, Zengli Zhang, Zhong Li
Cell Biology and Toxicology.2019; 35(4): 361. CrossRef
lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer
Mu Xu, Xiaoxiang Chen, Kang Lin, Kaixuan Zeng, Xiangxiang Liu, Xueni Xu, Bei Pan, Tao Xu, Li Sun, Bangshun He, Yuqin Pan, Huiling Sun, Shukui Wang
Journal of Hematology & Oncology.2019;[Epub] CrossRef
Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival
Kanchan Kumari, Biswajit Das, Amit K. Adhya, Arabinda K. Rath, Sandip K. Mishra
Scientific Reports.2019;[Epub] CrossRef
LncRNA ADAMTS9-AS2 promotes tongue squamous cell carcinoma proliferation, migration and EMT via the miR-600/EZH2 axis
Yingru Li, Quan Wan, Weiwei Wang, Lianxi Mai, Liujuan Sha, Mubarak Mashrah, Zhaoyu Lin, Chaobin Pan
Biomedicine & Pharmacotherapy.2019; 112: 108719. CrossRef
New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination
Helen Ma, Owen A. O’Connor, Enrica Marchi
Expert Review of Hematology.2019; 12(3): 137. CrossRef
iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?
Stephen W. Attwood, Michael J. Edel
Journal of Clinical Medicine.2019; 8(3): 288. CrossRef
Protein dynamics analysis reveals that missense mutations in cancer‐related genes appear frequently on hinge‐neighboring residues
Jan Fehmi Sayılgan, Türkan Haliloğlu, Mehmet Gönen
Proteins: Structure, Function, and Bioinformatics.2019; 87(6): 512. CrossRef
Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Is Required for Uterine Epithelial Integrity
Xin Fang, Nan Ni, John P. Lydon, Ivan Ivanov, Kayla J. Bayless, Monique Rijnkels, Qinglei Li
The American Journal of Pathology.2019; 189(6): 1212. CrossRef
Prolactin Receptor Signaling Regulates a Pregnancy-Specific Transcriptional Program in Mouse Islets
Mark E Pepin, Hayden H Bickerton, Maigen Bethea, Chad S Hunter, Adam R Wende, Ronadip R Banerjee
Endocrinology.2019; 160(5): 1150. CrossRef
Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation
Jie Zhou, Shuo Huang, Zhongyu Wang, Jiani Huang, Liang Xu, Xuefeng Tang, Yisong Y. Wan, Qi-jing Li, Alistair L. J. Symonds, Haixia Long, Bo Zhu
Nature Communications.2019;[Epub] CrossRef
Silencing of microRNA-708 promotes cell growth and epithelial-to-mesenchymal transition by activating the SPHK2/AKT/β-catenin pathway in glioma
Yan Chen, Xubin Deng, Weiquan Chen, Pengwei Shi, Mei Lian, Hongxiao Wang, Kewan Wang, Dadi Qian, Dong Xiao, Hao Long
Cell Death & Disease.2019;[Epub] CrossRef
EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia
Subazini Thankaswamy Kosalai, Mohammad Hamdy Abdelrazak Morsy, Nikos Papakonstantinou, Larry Mansouri, Niki Stavroyianni, Chandrasekhar Kanduri, Kostas Stamatopoulos, Richard Rosenquist, Meena Kanduri
Epigenetics.2019; 14(11): 1125. CrossRef
Current state of melanoma diagnosis and treatment
Lauren E. Davis, Sara C. Shalin, Alan J. Tackett
Cancer Biology & Therapy.2019; 20(11): 1366. CrossRef
DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
Chidimma Agatha Akpa, Karsten Kleo, Dido Lenze, Elisabeth Oker, Lora Dimitrova, Michael Hummel, Francesco Bertolini
PLOS ONE.2019; 14(8): e0220681. CrossRef
HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia
Zhengchang He, Siyu Zhang, Dan Ma, Qin Fang, Liping Yang, Shaoxian Shen, Ying Chen, Lingli Ren, Jishi Wang
Journal of Translational Medicine.2019;[Epub] CrossRef
Hematopoietic Differentiation of Human Pluripotent Stem Cells: HOX and GATA Transcription Factors as Master Regulators
Khaled Alsayegh, Lorena V. Cortés-Medina, Gerardo Ramos-Mandujano, Heba Badraiq, Mo Li
Current Genomics.2019; 20(6): 438. CrossRef
Long non‐coding small nucleolar RNA host genes in digestive cancers
Huan Yang, Zheng Jiang, Shuang Wang, Yongbing Zhao, Xiaomei Song, Yufeng Xiao, Shiming Yang
Cancer Medicine.2019; 8(18): 7693. CrossRef
Aberrant Expression of EZH2 in Pediatric Patients with Myelodysplastic Syndrome: A Potential Biomarker of Leukemic Evolution
Teresa de Souza Fernandez, Tatiana Fonseca Alvarenga, Elaiza Almeida Antônio de Kós, Viviane Lamim Lovatel, Rita de Cássia Tavares, Elaine Sobral da Costa, Cecília de Souza Fernandez, Eliana Abdelhay
BioMed Research International.2019; 2019: 1. CrossRef
Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet
Victor G. Martinez, Ester Munera-Maravilla, Alejandra Bernardini, Carolina Rubio, Cristian Suarez-Cabrera, Cristina Segovia, Iris Lodewijk, Marta Dueñas, Mónica Martínez-Fernández, Jesus Maria Paramio
Frontiers in Genetics.2019;[Epub] CrossRef
Cigarette smoke affects the onco-suppressor DAB2IP expression in bronchial epithelial cells of COPD patients
Giulia Anzalone, Giuseppe Arcoleo, Fabio Bucchieri, Angela M. Montalbano, Roberto Marchese, Giusy D. Albano, Caterina Di Sano, Monica Moscato, Rosalia Gagliardo, Fabio L. M. Ricciardolo, Mirella Profita
Scientific Reports.2019;[Epub] CrossRef
Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes
Garima Yagnik, Martin J. Rutowski, Sumedh S. Shah, Manish K. Aghi
Oncotarget.2019; 10(22): 2212. CrossRef
Genome‑wide analysis reveals the emerging roles of long non‑coding RNAs in cancer (Review)
Xiaoxia Ren
Oncology Letters.2019;[Epub] CrossRef
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
H Yamaguchi, Y Du, K Nakai, M Ding, S-S Chang, J L Hsu, J Yao, Y Wei, L Nie, S Jiao, W-C Chang, C-H Chen, Y Yu, G N Hortobagyi, M-C Hung
Oncogene.2018; 37(2): 208. CrossRef
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-d
Pei-Pei Kung, Patrick Bingham, Alexei Brooun, Michael Collins, Ya-Li Deng, Dac Dinh, Connie Fan, Ketan S. Gajiwala, Rita Grantner, Hovhannes J. Gukasyan, Wenyue Hu, Buwen Huang, Robert Kania, Susan E. Kephart, Cody Krivacic, Robert A. Kumpf, Penney Khamph
Journal of Medicinal Chemistry.2018; 61(3): 650. CrossRef
Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA
Kanchan Kumari, Biswajit Das, Amit Adhya, Sanjib Chaudhary, Shantibhusan Senapati, Sandip K. Mishra
Cell Death & Disease.2018;[Epub] CrossRef
Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription
Miao Wang, Chen Guo, Liang Wang, Gang Luo, Chao Huang, Yawei Li, Dong Liu, Fuqing Zeng, Guosong Jiang, Xingyuan Xiao
Cell Death & Disease.2018;[Epub] CrossRef
Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells
Zahre Sajadpoor, Zeinab Amini-Farsani, Hossein Teimori, Mehdi Shamsara, Mohammad Hossein Sangtarash, Payam Ghasemi-Dehkordi, Farrokh Yadollahi
Applied Biochemistry and Biotechnology.2018; 185(4): 1132. CrossRef
Epigenetic dysregulation of key developmental genes in radiation‐induced rat mammary carcinomas
Kazuhiro Daino, Mayumi Nishimura, Tatsuhiko Imaoka, Masaru Takabatake, Takamitsu Morioka, Yukiko Nishimura, Yoshiya Shimada, Shizuko Kakinuma
International Journal of Cancer.2018; 143(2): 343. CrossRef
The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma
Luca Sanna, Irene Marchesi, Mariarosa A. B. Melone, Luigi Bagella
Journal of Cellular Physiology.2018; 233(9): 6508. CrossRef
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer
Qingqing Ding, Yan Wang, Zhuang Zuo, Yun Gong, Savitri Krishnamurthy, Chia-Wei Li, Yun-Ju Lai, Wei Wei, Jing Wang, Ganiraju C. Manyam, Lixia Diao, Xinna Zhang, Feng Lin, William F. Symmans, Li Sun, Chang-Gong Liu, Xiuping Liu, Bisrat G. Debeb, Naoto T. Ue
Human Pathology.2018; 77: 121. CrossRef
EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer
Qiuju Wu, Zekun Chen, Guihua Zhang, Wenhui Zhou, You Peng, Rong Liu, Ceshi Chen, Jing Feng
Acta Biochimica et Biophysica Sinica.2018; 50(7): 693. CrossRef
Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells
Ewa Forma, Paweł Jóźwiak, Piotr Ciesielski, Agnieszka Zaczek, Katarzyna Starska, Magdalena Bryś, Anna Krześlak, Gokul M. Das
PLOS ONE.2018; 13(6): e0198351. CrossRef
Anti-tumor and anti-metastasis activities of honey bee larvae powder by suppressing the expression of EZH2
Masakatsu Kageyama, Kejuan Li, Shuang Sun, Guoqing Xing, Ran Gao, Zhongfang Lei, Zhenya Zhang
Biomedicine & Pharmacotherapy.2018; 105: 690. CrossRef
Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma
Yang Yu, Mingjiong Zhang, Ni Wang, Quanpeng Li, Jian Yang, Shuai Yan, Xuezhi He, Guozhong Ji, Lin Miao
Cell Death & Disease.2018;[Epub] CrossRef
Emerging roles of Myc in stem cell biology and novel tumor therapies
Go J. Yoshida
Journal of Experimental & Clinical Cancer Research.2018;[Epub] CrossRef
The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p
Mu Xu, Xiaoxiang Chen, Kang Lin, Kaixuan Zeng, Xiangxiang Liu, Bei Pan, Xueni Xu, Tao Xu, Xiuxiu Hu, Li Sun, Bangshun He, Yuqin Pan, Huiling Sun, Shukui Wang
Molecular Cancer.2018;[Epub] CrossRef
Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer
Xuefei Shi, Zhili Liu, Zhicong Liu, Xueren Feng, Feng Hua, Xixian Hu, Bin Wang, Kaihua Lu, Fengqi Nie
EBioMedicine.2018; 37: 177. CrossRef
DUXAP8, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2
Yifan Lian, Jiebin Yang, Yikai Lian, Chuangxing Xiao, Xuezhen Hu, Hongzhi Xu
Cancer Communications.2018; 38(1): 1. CrossRef
EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers
Marco Papale, Elisabetta Ferretti, Giuseppe Battaglia, Diana Bellavia, Antonello Mai, Marco Tafani
Frontiers in Pediatrics.2018;[Epub] CrossRef
Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2
Zaowen Song, Wencai Wu, Mengyun Chen, Wenzhao Cheng, Juntao Yu, Jinyong Fang, Lingling Xu, Jun-ichirou Yasunaga, Masao Matsuoka, Tiejun Zhao, Viviana Simon
Journal of Virology.2018;[Epub] CrossRef
MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia
Masanobu Tsubaki
YAKUGAKU ZASSHI.2018; 138(12): 1461. CrossRef
EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
Taylor Harding, Jessica Swanson, Brian Van Ness
Oncotarget.2018; 9(31): 21930. CrossRef
The untold stories of the speech gene, the FOXP2 cancer gene
Maria Jesus Herrero, Yorick Gitton
Genes & Cancer.2018; 9(1-2): 11. CrossRef
SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer
W Lu, S Liu, B Li, Y Xie, M G Izban, B R Ballard, S A Sathyanarayana, S E Adunyah, R J Matusik, Z Chen
Oncogene.2017; 36(10): 1364. CrossRef
Circ100284, via miR-217 regulation of EZH2, is involved in the arsenite-accelerated cell cycle of human keratinocytes in carcinogenesis
Junchao Xue, Yang Liu, Fei Luo, Xiaolin Lu, Hui Xu, Xinlu Liu, Lu Lu, Qianlei Yang, Chao Chen, Weimin Fan, Qizhan Liu
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2017; 1863(3): 753. CrossRef
Regulation of cancer epigenomes with a histone-binding synthetic transcription factor
David B. Nyer, Rene M. Daer, Daniel Vargas, Caroline Hom, Karmella A. Haynes
npj Genomic Medicine.2017;[Epub] CrossRef
Metastatic biomarkers in synovial sarcoma
Rosalia de Necochea-Campion, Lee M. Zuckerman, Hamid R. Mirshahidi, Shahrzad Khosrowpour, Chien-Shing Chen, Saied Mirshahidi
Biomarker Research.2017;[Epub] CrossRef
Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells
JingJing Wu, Qing Tang, LiJuan Yang, YuQing Chen, Fang Zheng, Swei Sunny Hann
Scientific Reports.2017;[Epub] CrossRef
Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3
Maureen M. Sherry-Lynes, Sejuti Sengupta, Shreya Kulkarni, Brent H. Cochran, Anita B. Hjelmeland
PLOS ONE.2017; 12(4): e0174775. CrossRef
Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines
Woo Sun Kwon, Sun Young Rha, Hei-Cheul Jeung, Tae Soo Kim, Hyun Cheol Chung
Biochemical Pharmacology.2017; 138: 163. CrossRef
Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors
Azadeh Amirnasr, Rob M. Verdijk, Patricia F. van Kuijk, Walter Taal, Stefan Sleijfer, Erik A. C. Wiemer, Marta M. Alonso
PLOS ONE.2017; 12(8): e0183155. CrossRef
Morphoproteomics, E6/E7 in-situ hybridization, and biomedical analytics define the etiopathogenesis of HPV-associated oropharyngeal carcinoma and provide targeted therapeutic options
Robert E. Brown, Syed Naqvi, Mary F. McGuire, Jamie Buryanek, Ron J. Karni
Journal of Otolaryngology - Head & Neck Surgery.2017;[Epub] CrossRef
Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation
Hyunjoo Kwon, Kyoungsub Song, Chang Han, Jinqiang Zhang, Lu Lu, Weina Chen, Tong Wu
The American Journal of Pathology.2017; 187(10): 2288. CrossRef
The role of EZH2 in overall survival of colorectal cancer: a meta-analysis
Laura Vilorio-Marqués, Vicente Martín, Cristina Diez-Tascón, María Francisca González-Sevilla, Tania Fernández-Villa, Emiliano Honrado, Veronica Davila-Batista, Antonio J. Molina
Scientific Reports.2017;[Epub] CrossRef
Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy
Huan Yu, Meng Ma, Junya Yan, Longwen Xu, Jiayi Yu, Jie Dai, Tianxiao Xu, Huan Tang, Xiaowen Wu, Siming Li, Bin Lian, Lili Mao, Zhihong Chi, Chuanliang Cui, Jun Guo, Yan Kong
Journal of Translational Medicine.2017;[Epub] CrossRef
Decreased expression of JMJD3 predicts poor prognosis of patients with clear cell renal cell carcinoma
Jiajun Wang, Li Liu, Qilai Long, Qi Bai, Yu Xia, Wei Xi, Jiejie Xu, Jianming Guo
Oncology Letters.2017; 14(2): 1550. CrossRef
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
Masanobu Tsubaki, Tomoya Takeda, Toshiki Kino, Kazuko Sakai, Tatsuki Itoh, Motohiro Imano, Takashi Nakayama, Kazuto Nishio, Takao Satou, Shozo Nishida
Oncotarget.2017; 8(24): 38717. CrossRef
Methylation-mediated silencing of microRNA-211 promotes cell growth and epithelial to mesenchymal transition through activation of the AKT/β-catenin pathway in GBM
Weidong Li, Xiaobo Miao, Lingling Liu, Yue Zhang, Xuejun Jin, Xiaojun Luo, Hai Gao, Xubin Deng
Oncotarget.2017; 8(15): 25167. CrossRef
EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis
Kei Ihira, Peixin Dong, Ying Xiong, Hidemichi Watari, Yosuke Konno, Sharon JB Hanley, Masayuki Noguchi, Noriyuki Hirata, Futoshi Suizu, Takahiro Yamada, Masataka Kudo, Noriaki Sakuragi
Oncotarget.2017; 8(8): 13509. CrossRef
Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells inï¿½vitro and inï¿½vivo
Fangfang Lu, Hong Xu, Qi Wang, Meiyi Li, Jiahua Meng, Yan Kuang
Oncology Letters.2017;[Epub] CrossRef
miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer
Hardik R. Mody, Sau Wai Hung, Rakesh K. Pathak, Jazmine Griffin, Zobeida Cruz-Monserrate, Rajgopal Govindarajan
Molecular Cancer Research.2017; 15(8): 1029. CrossRef
TET-Mediated Sequestration of miR-26 Drives EZH2 Expression and Gastric Carcinogenesis
Min Deng, Ruixin Zhang, Zhengxi He, Qinwei Qiu, Xihong Lu, Jiang Yin, Hao Liu, Xiaoting Jia, Zhimin He
Cancer Research.2017; 77(22): 6069. CrossRef
The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications
Soo Hee Kim, Woo Ick Yang, Yoo Hong Min, Young Hyeh Ko, Sun Och Yoon
Tumor Biology.2016; 37(2): 2037. CrossRef
Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression
Liqiong Cai, Zehua Wang, Denghua Liu
Tumor Biology.2016; 37(5): 6359. CrossRef
The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane
Matthew L. Fisher, Gautam Adhikary, Dan Grun, David M. Kaetzel, Richard L. Eckert
Molecular Carcinogenesis.2016; 55(12): 2024. CrossRef
Problems of glioblastoma multiforme drug resistance
A. A. Stavrovskaya, S. S. Shushanov, E. Yu. Rybalkina
Biochemistry (Moscow).2016; 81(2): 91. CrossRef
High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer
Si-Hyong Jang, Jong Eun Lee, Mee-Hye Oh, Ji-Hye Lee, Hyun Deuk Cho, Kyung-Ju Kim, Sung Yong Kim, Sun Wook Han, Han Jo Kim, Sang Byung Bae, Hyun Ju Lee
Journal of Breast Cancer.2016; 19(1): 53. CrossRef
Expression of Mirna-26B in the Diagnosis and Prognosis of Patients with Non-Small-Cell Lung Cancer
Li-Peng Jiang, Zhi-Tu Zhu, Chun-Yan He
Future Oncology.2016; 12(9): 1105. CrossRef
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Sebastian Carotta
Frontiers in Immunology.2016;[Epub] CrossRef
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
Fade Mahmoud, Bradley Shields, Issam Makhoul, Laura F. Hutchins, Sara C. Shalin, Alan J. Tackett
Cancer Biology & Therapy.2016; 17(6): 579. CrossRef
Prognostic value of UTX expression in patients with clear cell renal cell carcinoma
Jiajun Wang, Li Liu, Wei Xi, Qilai Long, Yiwei Wang, Qi Bai, Yu Xia, Jiejie Xu, Jianming Guo
Urologic Oncology: Seminars and Original Investigations.2016; 34(8): 338.e19. CrossRef
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
G. Paolo Dotto, Anil K. Rustgi
Cancer Cell.2016; 29(5): 622. CrossRef
Genomic and Epigenomic Alterations in Cancer
Balabhadrapatruni V.S.K. Chakravarthi, Saroj Nepal, Sooryanarayana Varambally
The American Journal of Pathology.2016; 186(7): 1724. CrossRef
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
Yusuke Furukawa, Jiro Kikuchi
International Journal of Hematology.2016; 104(3): 281. CrossRef
Down-Regulation of TSLP After EZH2 Silencing in ESCC Cell Line
Gholamreza Karami Madani, Abolfazl Rad, Mohammad Mahdi Forghanifard
Journal of Biomedicine.2016;[Epub] CrossRef
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas
Maria Ramaglia, Velia D’Angelo, Adriana Iannotta, Daniela Di Pinto, Elvira Pota, Maria Carmen Affinita, Vittoria Donofrio, Maria Elena Errico, Angela Lombardi, Cristiana Indolfi, Fiorina Casale, Michele Caraglia
Cancer Cell International.2016;[Epub] CrossRef
DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity
Y Wang, H Sun, J Wang, H Wang, L Meng, C Xu, M Jin, B Wang, Y Zhang, Y Zhang, T Zhu
Cell Death & Disease.2016; 7(7): e2316. CrossRef
Significance of EZH2 expression in canine mammary tumors
Hyun-Ji Choi, Sungwoong Jang, Jae-Eun Ryu, Hyo-Ju Lee, Han-Byul Lee, Woo-Sung Ahn, Hye-Jin Kim, Hyo-Jin Lee, Hee Jin Lee, Gyung-Yub Gong, Woo-Chan Son
BMC Veterinary Research.2016;[Epub] CrossRef
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitabl
Rishi G. Vaswani, Victor S. Gehling, Les A. Dakin, Andrew S. Cook, Christopher G. Nasveschuk, Martin Duplessis, Priyadarshini Iyer, Srividya Balasubramanian, Feng Zhao, Andrew C. Good, Robert Campbell, Christina Lee, Nico Cantone, Richard T. Cummings, Emm
Journal of Medicinal Chemistry.2016; 59(21): 9928. CrossRef
MiR-101 Targets the EZH2/Wnt/β-Catenin the Pathway to Promote the Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells
Hongrui Wang, Yake Meng, Quanjun Cui, Fujun Qin, Haisong Yang, Yu Chen, Yajun Cheng, Jiangang Shi, Yongfei Guo
Scientific Reports.2016;[Epub] CrossRef
EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells
Ming-Quan Sha, Xiao-Li Zhao, Liang Li, Li-Hui Li, Yi Li, Tian-Geng Dong, Wei-Xin Niu, Li-Jun Jia, Rong-Guang Shao, Yong-Su Zhen, Zhen Wang
Cell Death & Disease.2016; 7(11): e2486. CrossRef
Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report
Joseph Hatem, April M. Schrank-Hacker, Christopher D. Watt, Jennifer J. D. Morrissette, Adam I. Rubin, Ellen J. Kim, Sunita D. Nasta, Mariusz A. Wasik, Agata M. Bogusz
Diagnostic Pathology.2016;[Epub] CrossRef
Expression Profile and Function Analysis of LncRNAs during Priming Phase of Rat Liver Regeneration
Jun Li, Wei Jin, Yanli Qin, Weiming Zhao, Cuifang Chang, Cunshuan Xu, Klaus Roemer
PLOS ONE.2016; 11(6): e0156128. CrossRef
Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer
Cortney L. Lawrence, Albert S. Baldwin, Aamir Ahmad
PLOS ONE.2016; 11(10): e0165005. CrossRef
Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids
Qiwei Yang, Archana Laknaur, Lelyand Elam, Nahed Ismail, Larisa Gavrilova-Jordan, John Lue, Michael P. Diamond, Ayman Al-Hendy
Reproductive Sciences.2016; 23(10): 1314. CrossRef
The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway
Hiroyoshi Kurihara, Reo Maruyama, Kazuya Ishiguro, Shinichi Kanno, Itaru Yamamoto, Keisuke Ishigami, Kei Mitsuhashi, Hisayoshi Igarashi, Miki Ito, Tokuma Tanuma, Yasutaka Sukawa, Kenji Okita, Tadashi Hasegawa, Kohzoh Imai, Hiroyuki Yamamoto, Yasuhisa Shin
Oncotarget.2016; 7(11): 12704. CrossRef
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia
Nikos Papakonstantinou, Stavroula Ntoufa, Elisavet Chartomatsidou, Konstantia Kotta, Andreas Agathangelidis, Lefki Giassafaki, Tzeni Karamanli, Panagiota Bele, Theodoros Moysiadis, Panagiotis Baliakas, Lesley Ann Sutton, Niki Stavroyianni, Achilles Anagno
Oncotarget.2016; 7(24): 35946. CrossRef
Proximal and distal regulation of the HYAL1 gene cluster by the estrogen receptor α in breast cancer cells
Lydia Edjekouane, Samira Benhadjeba, Maïka Jangal, Hubert Fleury, Nicolas Gévry, Euridice Carmona, André Tremblay
Oncotarget.2016; 7(47): 77276. CrossRef
Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
Ranran Sun, Jacson Shen, Yan Gao, Yubing Zhou, Zujiang Yu, Francis Hornicek, Quancheng Kan, Zhenfeng Duan
Oncotarget.2016; 7(25): 38333. CrossRef
GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers
How-Wen Ko, Heng-Huan Lee, Longfei Huo, Weiya Xia, Cheng-Chieh Yang, Jennifer L. Hsu, Long-Yuan Li, Chien-Chen Lai, Li-Chuan Chan, Chien-Chia Cheng, Adam M. Labaff, Hsin-Wei Liao, Seung-Oe Lim, Chia-Wei Li, Yongkun Wei, Lei Nie, Hirohito Yamaguchi, Mien-C
Oncotarget.2016; 7(35): 57131. CrossRef
Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma
Youtao Xu, Jie Wang, Mantang Qiu, Lei Xu, Ming Li, Feng Jiang, Rong Yin, Lin Xu
Tumor Biology.2015; 36(3): 1643. CrossRef
Role of the ubiquitin proteasome system in hematologic malignancies
Anagh A. Sahasrabuddhe, Kojo S. J. Elenitoba‐Johnson
Immunological Reviews.2015; 263(1): 224. CrossRef
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer
Lili Liao, Joseph R. Testa, Haifeng Yang
Cancer Genetics.2015; 208(5): 206. CrossRef
The role of aberrant proteolysis in lymphomagenesis
Anagh A. Sahasrabuddhe, Kojo S.J. Elenitoba-Johnson
Current Opinion in Hematology.2015; 22(4): 369. CrossRef
Small Molecule Inhibitors of EZH2: the Emerging Translational Landscape
Heike Keilhack, Jesse J Smith
Epigenomics.2015; 7(3): 337. CrossRef
Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma
Yang-Fan Lv, Guang-Ning Yan, Gang Meng, Xi Zhang, Qiao-Nan Guo
Scientific Reports.2015;[Epub] CrossRef
Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma
Mehnaz Khan, Laura L Walters, Qiang Li, Dafydd G Thomas, Jason M L Miller, Qitao Zhang, Andrew P Sciallis, Yu Liu, Brian J Dlouhy, Patrice E Fort, Steven M Archer, Hakan Demirci, Yali Dou, Rajesh C Rao
Laboratory Investigation.2015; 95(11): 1278. CrossRef
Methyltransferase expression and tumor suppressor gene methylation in sporadic and familial colorectal cancer
Emmi I. Joensuu, Taina T. Nieminen, Johanna E. Lotsari, Walter Pavicic, Wael M. Abdel‐Rahman, Päivi Peltomäki
Genes, Chromosomes and Cancer.2015; 54(12): 776. CrossRef
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
Jiro Kikuchi, Daisuke Koyama, Taeko Wada, Tohru Izumi, Peter O. Hofgaard, Bjarne Bogen, Yusuke Furukawa
Journal of Clinical Investigation.2015; 125(12): 4375. CrossRef
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters
Nathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, Martina Kluth, Claudia Hube-Magg, Sarah Minner, Christina Koop, Markus Graefen, Hans Heinzer, Corinna Wittmer, Guido Sauter, Waldemar Wilczak, Hartwig Huland, Ronald Simon, Thorsten Schlomm, Ste
Carcinogenesis.2015; 36(11): 1333. CrossRef
EZH2 in Bladder Cancer, a Promising Therapeutic Target
Mónica Martínez-Fernández, Carolina Rubio, Cristina Segovia, Fernando López-Calderón, Marta Dueñas, Jesús Paramio
International Journal of Molecular Sciences.2015; 16(11): 27107. CrossRef
siRNA Silencing EZH2 Reverses Cisplatin-resistance of Human Non-small Cell Lung and Gastric Cancer Cells
Wen Zhou, Jian Wang, Wang-Ying Man, Qing-Wei Zhang, Wen-Gui Xu
Asian Pacific Journal of Cancer Prevention.2015; 16(6): 2425. CrossRef
H3K27me3 is an Epigenetic Mark of Relevance in Endometriosis
Mariano Colón-Caraballo, Janice B. Monteiro, Idhaliz Flores
Reproductive Sciences.2015; 22(9): 1134. CrossRef
A Gene Regulatory Program in Human Breast Cancer
Renhua Li, John Campos, Joji Iida
Genetics.2015; 201(4): 1341. CrossRef
MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells
Xiaoping Liu, Qianqian Lei, Zhibin Yu, Gang Xu, Hailin Tang, Wei Wang, Zeyou Wang, Guiyuan Li, Minghua Wu
Oncotarget.2015; 6(10): 7930. CrossRef
Enhancer of zeste acts as a major developmental regulator ofCiona intestinalisembryogenesis
Emilie Le Goff, Camille Martinand-Mari, Marianne Martin, Jérôme Feuillard, Yvan Boublik, Nelly Godefroy, Paul Mangeat, Stephen Baghdiguian, Giacomo Cavalli
Biology Open.2015; 4(9): 1109. CrossRef

42,127 View
862 Download
241 Web of Science
215 Crossref

Original Articles

Cost-Effectiveness of Liver Cancer Screening in Adults at High Risk for Liver Cancer in the Republic of Korea: Young Hwa Lee, Kui Son Choi, Jae Kwan Jun, Mina Suh, Hoo-Yeon Lee, Youn Nam Kim, Chung Mo Nam, Eun-Cheol Park, Woo-Hyun Cho; Cancer Res Treat. 2014;46(3):223-233. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.223

Abstract PDF PubReader ePub

Purpose
This study was conducted in order to determine the most cost-effective strategy, in terms of interval and age range, forliver cancer screening in the high-risk population of Korea. Materials and Methods A stochastic modelwas used to simulate the cost-effectiveness ofliver cancer screening by combined ultrasonography and alpha-fetoprotein testing when varying both screening intervals and age ranges. The effectiveness of these screening strategies in the high-risk population was defined as the probability of detecting preclinical liver cancer, and costwas based on the direct cost ofthe screening and confirmative tests. Optimal cost-effectiveness was determined using the incremental cost-effectiveness ratio. Results Among the 36 alternative strategies, one-year or two-year interval screening for men aged between 50 and 80 years, six-month or one-year interval screening for men aged between 40 and 80 years, and six-month interval screening for men aged between 30 and 80 years were identified as non-dominated strategies. For women, identified non-dominated strategies were: one-year interval screening between age 50 and 65 years, one-year or six-month interval screening between age 50 and 80 years, six-month interval screening between age 40 and 80 years, and six-month interval screening between age 30 and 80 years. Conclusion In Korea, a one-year screening interval for men aged 50 to 80 years would be marginally cost-effective. Further studies should be conducted in order to evaluate effectiveness of liver cancer screening, and compare the cost effectiveness of different liver cancer screening programs with a final outcome indicator such as qualityadjusted life-years or disability-adjusted life-years.

Citations

Citations to this article as recorded by

Alcoholic liver disease in relation to cancer incidence and mortality: Findings from a large, matched cohort study in South Korea
Thi Phuong Thao Tran, Minji Han, Ngoc Minh Luu, Jin‐Kyoung Oh
Cancer Medicine.2023; 12(7): 8754. CrossRef
A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies
Anh Le Tuan Nguyen, Hoa Thi Thu Nguyen, Kwang Chien Yee, Andrew J. Palmer, Christopher Leigh Blizzard, Barbara de Graaff
Value in Health.2021; 24(5): 733. CrossRef
Disparities in Liver Cancer Surveillance Among People With Disabilities
Jae Youn Seo, Dong Wook Shin, Su Jong Yu, Jin Hyung Jung, Kyungdo Han, In Young Cho, So Young Kim, Kui Son Choi, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Journal of Clinical Gastroenterology.2021; 55(5): 439. CrossRef
The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea
Jin Won Kwon, Ha Jin Tchoe, Jayoun Lee, Jae Kyung Suh, Jeong-Hoon Lee, Sangjin Shin
Gut and Liver.2020; 14(1): 108. CrossRef

12,134 View
105 Download
5 Web of Science
4 Crossref

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer: Hyun Jung Lee, Dae-Seog Heo, Joo-Youn Cho, Sae-Won Han, Hye-Jung Chang, Hyeon-Gyu Yi, Tae-Eun Kim, Se-Hoon Lee, Do-Youn Oh, Seock-Ah Im, In-Jin Jang, Yung-Jue Bang; Cancer Res Treat. 2014;46(3):234-242. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.234

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A, which is an inhibitor of P-glycoprotein, in patients with advanced cancers. Materials and Methods Patients with advanced solid tumors received standard therapy were given the study drug at escalating doses, using a 3+3 design. The study drug was orally administered on days 1, 8, and 15, with a 28-day cycle of administration. The dose of paclitaxel was escalated from 60 to 420 mg/m², and the dose of HM30181A was escalated from 30-210 mg/m². Results A total of twenty-four patients were enrolled. Only one patient experienced a doselimiting toxicity—a grade 3 neutropenia that persisted for more than 2 weeks, at 240 mg/m² of paclitaxel. MTD was not reached. The maximum plasma concentration was obtained at a dose level of 300 mg/m² and the area under the curve of plasma concentration- time from 0 to the most recent plasma concentration measurement of paclitaxel was reached at a dose level of 420 mg/m². The absorption of paclitaxel tends to be limited at doses that exceed 300 mg/m². The effective plasma concentration of paclitaxel was achieved at a dose of 120 mg/m². Responses of 23 patients were evaluated; 8 (34.8%) had stable disease and 15 (65.2%) had progressive disease. Conclusion The study drug appears to be well tolerated, and the effective plasma concentration of paclitaxel was achieved. The recommended phase II dose for oral paclitaxel is 300 mg/m².

Citations

Citations to this article as recorded by

Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro
Shruti Vig, Payal Srivastava, Idrisa Rahman, Renee Jaranson, Anika Dasgupta, Robert Perttilä, Petteri Uusimaa, Huang-Chiao Huang
Cancer Drug Resistance.2024;[Epub] CrossRef
Pharmacokinetic modulation of substrate drugs via the inhibition of drug-metabolizing enzymes and transporters using pharmaceutical excipients
Min-Koo Choi, Jihoon Lee, Im-Sook Song
Journal of Pharmaceutical Investigation.2023; 53(1): 1. CrossRef
Redox-responsive drug-inhibitor conjugate encapsulated in DSPE-PEG2k micelles for overcoming multidrug resistance to chemotherapy
Penghui Wang, Yuling Wang, Xuelin Xia, Wei Huang, Deyue Yan
Biomaterials Science.2023; 11(12): 4335. CrossRef
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors
Jimmy He, Christopher G. C. A. Jackson, Sanjeev Deva, Tak Hung, Katriona Clarke, Eva Segelov, Tsu‐Yi Chao, Ming‐Shen Dai, Hsien‐Tang Yeh, Wen Wee Ma, Douglas Kramer, Wing‐Kai Chan, Rudolf Kwan, David Cutler, Jay Zhi
CPT: Pharmacometrics & Systems Pharmacology.2022; 11(7): 867. CrossRef
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies
Wen Wee Ma, Jenny J. Li, Nilofer S. Azad, Elaine T. Lam, Jennifer R. Diamond, Grace K. Dy, Mateusz Opyrchal, Jay Zhi, Douglas Kramer, Wing-Kai Chan, David Cutler, Rudolf Kwan, Alex A. Adjei, Antonio Jimeno
Cancer Chemotherapy and Pharmacology.2022; 90(1): 7. CrossRef
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance
Hai Wang, Yutong Liang, Yue Yin, Jie Zhang, Wen Su, Alisa M. White, Bin Jiang, Jiangsheng Xu, Yuntian Zhang, Samantha Stewart, Xiongbin Lu, Xiaoming He
Nature Communications.2021;[Epub] CrossRef
The Intravenous to Oral Switch of Taxanes: Strategies and Current Clinical Developments
Marit A C Vermunt, Andries M Bergman, Eric van der Putten, Jos H Beijnen
Future Oncology.2021; 17(11): 1379. CrossRef
Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice
Mahdi Ghadi, Seyed Jalal Hosseinimehr, Fereshteh Talebpour Amiri, Alireza Mardanshahi, Zohreh Noaparast
European Journal of Pharmacology.2021; : 173892. CrossRef
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
Michael P. Smolinski, Sameer Urgaonkar, Laura Pitzonka, Murray Cutler, GwanSun Lee, Kwee Hyun Suh, Johnson Y. N. Lau
Journal of Medicinal Chemistry.2021; 64(7): 3677. CrossRef
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study
Christopher G. C. A. Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Blair McLaren, Noelyn Anne Hung, Katriona Clarke, Tsu‐Yi Chao, Ming‐Shen Dai, Hsien‐Tang Yeh, David L. Cutler, Douglas Kramer, Jimmy He, Jay Zhi, Wing‐Kai Chan, Rudolf Kwan, S
British Journal of Clinical Pharmacology.2021; 87(12): 4670. CrossRef
Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin
Yuanfeng Wei, Shengyan Zhou, Tianyun Hao, Jianjun Zhang, Yuan Gao, Shuai Qian
European Journal of Pharmaceutical Sciences.2019; 129: 21. CrossRef
DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy
Eunseo Jang, Minhee Son, Junhee Jang, In-Hyun Lee, Sol Kim, Taejun Kwon, Yong-hyun Jeon, Woo-Suk Koh, Kil-Soo Kim, Sang Kyoon Kim, Sumitra Deb
PLOS ONE.2019; 14(11): e0225095. CrossRef
Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles
Marco C. Cavaco, Carolina Pereira, Bruna Kreutzer, Luis F. Gouveia, Beatriz Silva-Lima, Alexandra M. Brito, Mafalda Videira
European Journal of Pharmaceutics and Biopharmaceutics.2017; 110: 76. CrossRef
Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor
Jin Cheul Kim, Kyeong Soo Kim, Dong Shik Kim, Sung Giu Jin, Dong Wuk Kim, Yong Il Kim, Jae-Hyun Park, Jong Oh Kim, Chul Soon Yong, Yu Seok Youn, Jong Soo Woo, Han-Gon Choi
International Journal of Pharmaceutics.2016; 506(1-2): 93. CrossRef
Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate
Ramesh Soundararajan, Kenji Sasaki, Lisa Godfrey, Uchechukwu Odunze, Nancy Fereira, Andreas Schätzlein, Ijeoma Uchegbu
International Journal of Pharmaceutics.2016; 514(1): 121. CrossRef

16,954 View
166 Download
17 Web of Science
16 Crossref

Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06): Jae Myoung Noh, Won Park, Jae-Sung Kim, Woong Sub Koom, Jin Hee Kim, Doo Ho Choi, Hee Chul Park; Cancer Res Treat. 2014;46(3):243-249. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.243

Abstract PDF PubReader ePub

Purpose
The aim of this study was to examine the clinical implications of a pathologically complete response after neoadjuvant chemoradiotherapy (CRT) followed by local excision for patients with cT2 rectal cancer who refused radical surgery. Materials and Methods Seventeen patients with cT2 primary rectal cancer within 6 cm from the anal verge who received neoadjuvant CRT and local excision because of patient refusal of radical surgery or poor performance status were included. Two patients had clinical involvement of a regional lymph node. Preoperative radiotherapy was delivered to the whole pelvis at a dose of 44 to 50.4 Gy in 22 to 28 fractions. All patients underwent transanal excision and eight patients (47%) received postoperative chemotherapy. Results Ten patients (59%) achieved ypT0. At a median follow-up period of 75 months (range, 22 to 126 months), four (24%) patients developed recurrence (two locoregional and two distant). The 5-year disease-free survival of all patients was 82%, and was higher in patients with ypT0 (90%) than in patients with ypT1-2 (69%, p=0.1643). Decreased disease-free survival was also observed in patients receiving capecitabine compared with 5-fluorouracil (54% vs. 100%, p=0.0298). Conclusion Local excision could be a feasible alternative to radical surgery in patients with ypT0 after neoadjuvant CRT for cT2 distal rectal cancer without further radical surgery.

Citations

Citations to this article as recorded by

Towards personalized treatment of T2N0 rectal cancer: A systematic review of long‐term oncological outcomes of neoadjuvant therapy followed by local excision
Roberto Peltrini, Nicola Imperatore, Maria Michela Di Nuzzo, Gianluca Pellino
Journal of Gastroenterology and Hepatology.2022; 37(8): 1426. CrossRef
Preoperative concurrent chemoradiotherapy MRI characteristics favouring pathologic complete response in patients with rectal cancer: Usefulness of MR T2‐stage as an ancillary finding for predicting pathologic complete response
Hyeon Jin Lee, Woo‐Suk Chung, Ji hae An, Jung Hoon Kim
Journal of Medical Imaging and Radiation Oncology.2021; 65(2): 166. CrossRef
MR prediction of pathologic complete response and early-stage rectal cancer after neoadjuvant chemoradiation in patients with clinical T1/T2 rectal cancer for organ saving strategy
Heejin Bae, Nieun Seo, Kyunghwa Han, Woong Sub Koom, Myeong-Jin Kim, Nam Kyu Kim, Joon Seok Lim
Medicine.2020; 99(42): e22746. CrossRef
Does total regression of primary rectal cancer after preoperative chemoradiotherapy represent “no tumor” status?
Seong-A Jeong, In Ja Park, Seung Mo Hong, Jun Woo Bong, Hye Yoon Choi, Ji Hyun Seo, Hyong Eun Kim, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Annals of Surgical Treatment and Research.2019; 96(2): 78. CrossRef
Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection
Oliver K. Jawitz, Mohamed A. Adam, Megan C. Turner, Brian F. Gilmore, John Migaly
Surgery.2019; 165(6): 1193. CrossRef
Status for clinically complete remission rectal cancer after concomitant chemo-radiotherapy in Taiwan
Geng-Ping Lin, Kuan-Der Lee, Jeng-Yi Wang, Jinn-Shiun Chen, Chun-Ju Chiang, Chien-Yuh Yeh
Asian Journal of Surgery.2018; 41(3): 203. CrossRef
Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer
Laurence Bernier, Svetlana Balyasnikova, Diana Tait, Gina Brown
Current Colorectal Cancer Reports.2018; 14(2): 37. CrossRef
Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score–Matched Analysis
Young Seob Shin, Jin-hong Park, Sang Min Yoon, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Kyu-pyo Kim, Eun Kyung Choi, Seung Do Ahn, Sang-Wook Lee, Jong Hoon Kim
International Journal of Radiation Oncology*Biology*Physics.2018; 101(3): 630. CrossRef
Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy?
Bo Young Oh, Jung Wook Huh, Woo Yong Lee, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun
Cancer Research and Treatment.2018; 50(3): 634. CrossRef
Local Excision Techniques for Rectal Cancer After Neoadjuvant Chemoradiotherapy: What Are We Doing?
Fraser McLean Smith, Abdul Ahad, Rodrigo Oliva Perez, John Marks, Krzysztof Bujko, Richard J. Heald
Diseases of the Colon & Rectum.2017; 60(2): 228. CrossRef
Transanal Minimally Invasive Surgery: Review of Indications and Outcomes from 75 Consecutive Patients
Deborah S. Keller, Reena N. Tahilramani, Juan R. Flores-Gonzalez, Ali Mahmood, Eric M. Haas
Journal of the American College of Surgeons.2016; 222(5): 814. CrossRef
Lymphknotenmetastasen beim ypT1/2-Rektumkarzinom nach neoadjuvanter Radiochemotherapie
T. Sprenger, H. Rothe, T. Beissbarth, L.-C. Conradi, A. Kauffels, K. Homayounfar, C. L. Behnes, C. Rödel, T. Liersch, M. Ghadimi
Der Chirurg.2016; 87(7): 593. CrossRef
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer
Sung Min Jung, Chang Sik Yu, In Ja Park, Tae Won Kim, Jong Hoon Kim, Yong Sik Yoon, Seok-Byung Lim, Jin Cheon Kim
Medicine.2016; 95(20): e3718. CrossRef
A Systematic Review of Local Excision After Neoadjuvant Therapy for Rectal Cancer: Are ypT0 Tumors the Limit?
Sally Hallam, David E. Messenger, Michael G. Thomas
Diseases of the Colon & Rectum.2016; 59(10): 984. CrossRef
Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer
Young Seob Shin, Yong sik Yoon, Seok-Byung Lim, Chang Sik Yu, Tae Won Kim, Heung Moon Chang, Jin-hong Park, Seung Do Ahn, Sang-Wook Lee, Eun Kyung Choi, Jin Cheon Kim, Jong Hoon Kim
Radiation Oncology Journal.2016; 34(3): 177. CrossRef
Why the Conventional Parks Transanal Excision for Early Stage Rectal Cancer Should Be Abandoned
Sam Atallah, Deborah Keller
Diseases of the Colon & Rectum.2015; 58(12): 1211. CrossRef
Influence of Preoperative Chemoradiotherapy on the Surgical Strategy According to the Clinical T Stage of Patients With Rectal Cancer
In Ja Park, Jong Lyul Lee, Yong Sik Yoon, Chan Wook Kim, Seok-Byung Lim, Jong Seok Lee, Seong Ho Park, Jin Hong Park, Jong Hoon Kim, Chang Sik Yu, Jin Cheon Kim
Medicine.2015; 94(52): e2377. CrossRef
Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation
Juefeng Wan, Kaitai Liu, Ji Zhu, Guichao Li, Zhen Zhang
Oncotarget.2015; 6(13): 11714. CrossRef
Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: Pooled analysis of KROG 10-01 and 11-02
Jong Hoon Lee, Hong Seok Jang, Jun-Gi Kim, Myung Ah Lee, Dae Yong Kim, Tae Hyun Kim, Jae Hwan Oh, Sung Chan Park, Sun Young Kim, Ji Yeon Baek, Hee Chul Park, Hee Cheol Kim, Taek-Keun Nam, Eui Kyu Chie, Ji-Han Jung, Seong Taek Oh
Radiotherapy and Oncology.2014; 113(1): 18. CrossRef

12,559 View
75 Download
20 Web of Science
19 Crossref

A Case-Control Study to Identify Risk Factors for Totally Implantable Central Venous Port-Related Bloodstream Infection: Guk Jin Lee, Sook Hee Hong, Sang Young Roh, Sa Rah Park, Myung Ah Lee, Hoo Geun Chun, Young Seon Hong, Jin Hyoung Kang, Sang Il Kim, Youn Jeong Kim, Ho Jong Chun, Jung Suk Oh; Cancer Res Treat. 2014;46(3):250-260. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.250

Abstract PDF PubReader ePub

Purpose
To date, the risk factors for central venous port-related bloodstream infection (CVPBSI) in solid cancer patients have not been fully elucidated. We conducted this study in order to determine the risk factors for CVP-BSI in patients with solid cancer.
Materials and Methods
A total of 1,642 patients with solid cancer received an implantable central venous port for delivery of chemotherapy between October 2008 and December 2011 in a single center. CVP-BSI was diagnosed in 66 patients (4%). We selected a control group of 130 patients, who were individually matched with respect to age, sex, and catheter insertion time.
Results
CVP-BSI occurred most frequently between September and November (37.9%). The most common pathogen was gram-positive cocci (n=35, 53.0%), followed by fungus (n=14, 21.2%). Multivariate analysis identified monthly catheter-stay as a risk factor for CVP-BSI (p=0.000), however, its risk was lower in primary gastrointestinal cancer than in other cancer (p=0.002). Initial metastatic disease and long catheter-stay were statistically significant factors affecting catheter life span (p=0.005 and p=0.000). Results of multivariate analysis showed that recent transfusion was a risk factor for mortality in patients with CVP-BSI (p=0.047).
Conclusion
In analysis of the results with respect to risk factors, prolonged catheter-stay should be avoided as much as possible. It is necessary to be cautious of CVP-BSI in metastatic solid cancer, especially non-gastrointestinal cancer. In addition, avoidance of unnecessary transfusion is essential in order to reduce the mortality of CVP-BSI. Finally, considering the fact that confounding factors may have affected the results, conduct of a well-designed prospective controlled study is warranted.

Citations

Citations to this article as recorded by

Risk Factors of the Totally Implantable Venous Access Device-Related Infection in Patients With Brain Tumors Undergoing Chemotherapy After Surgery
Haihong Li, Jing Shan
Surgical Infections.2024; 25(2): 133. CrossRef
An analysis of totally implantable central venous port system infections in an urban tertiary referral center
Ulrich Krümpelmann, Ahmed Boseila, Mathias Löhnert, Olaf Kaup, Jacob J. Clarenbach, Martin Görner
Journal of Chemotherapy.2021; 33(4): 228. CrossRef
Use of catheter with 2-methacryloyloxyethyl phosphorylcholine polymer coating is associated with long-term availability of central venous port
Yuuki Iida, Kumiko Hongo, Takanobu Onoda, Yusuke Kita, Yukio Ishihara, Naoki Takabayashi, Ryo Kobayashi, Takeyuki Hiramatsu
Scientific Reports.2021;[Epub] CrossRef
Clinical Characteristics and Risk Factors of Long-term Central Venous Catheter–associated Bloodstream Infections in Children
Hye Min Moon, Suji Kim, Ki Wook Yun, Hyun-young Kim, Sung Eun Jung, Eun Hwa Choi, Hoan Jong Lee
Pediatric Infectious Disease Journal.2018; 37(5): 401. CrossRef
Risk factors for health care–associated infection in hospitalized adults: Systematic review and meta-analysis
Alba Luz Rodríguez-Acelas, Miriam de Abreu Almeida, Bruna Engelman, Wilson Cañon-Montañez
American Journal of Infection Control.2017; 45(12): e149. CrossRef
WITHDRAWN: Prevention of peripherally inserted central catheter-related infections in very low-birth-weight infants by using a central line bundle guideline with a standard checklist
Chen Yuan, Qing Zhao, Xiaoyan Song, Fei Meng
International Journal of Nursing Sciences.2016; 3(1): 50. CrossRef
Prevention of peripherally inserted central line-associated blood stream infections in very low-birth-weight infants by using a central line bundle guideline with a standard checklist: a case control study
Wei Wang, Chunling Zhao, Qinglian Ji, Ying Liu, Guirong Shen, Lili Wei
BMC Pediatrics.2015;[Epub] CrossRef
Central venous access in oncology: ESMO Clinical Practice Guidelines
B. Sousa, J. Furlanetto, M. Hutka, P. Gouveia, R. Wuerstlein, J.M. Mariz, D. Pinto, F. Cardoso
Annals of Oncology.2015; 26: v152. CrossRef
Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli
Jui-Feng Hsu, Hsu-Liang Chang, Ming-Ju Tsai, Ying-Ming Tsai, Yen-Lung Lee, Pei-Huan Chen, Wen-Chieh Fan, Yu-Chung Su, Chih-Jen Yang
World Journal of Surgical Oncology.2015;[Epub] CrossRef

13,196 View
119 Download
11 Web of Science
9 Crossref

Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma: Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2014;46(3):261-269. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.261

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to evaluate the outcome of low-dose whole brain radiotherapy (WBRT) with tumor bed boost after methotrexate-based chemotherapy in the management of primary central nervous system lymphoma (PCNSL). Materials and Methods We retrospectively analyzed 64 patients with pathologically proven PCNSL between 2000 and 2011. Methotrexate-based chemotherapy with a median of five cycles was followed by radiotherapy to the whole brain and to the initial tumor bed. The median dose to the whole brain and to the tumor bed was 27 Gy (range, 18 to 36 Gy) and 50.4 Gy (range, 45 to 54 Gy), respectively. Results With a median follow-up period of 27 months, 55 patients (85.9%) achieved complete response (CR). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 52.6% and 39.3%, respectively. In univariate analysis, factors associated with OS were age, performance status, involvement of deep structure, and CR to sequential chemoradiotherapy (CRT). These variables remained as significant factors for OS in multivariate analysis. CR to sequential CRT was the only positive factor associated with PFS (p=0.009). Neurologic toxicity was more common in elderly patients older than 60 years (p=0.025). Conclusion Low-dose WBRT with tumor bed boost after methotrexate-based chemotherapy might be an effective method for management of PCNSL.

Citations

Citations to this article as recorded by

A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma
Sara Steffanoni, Teresa Calimeri, Nicoletta Anzalone, Sara Mastaglio, Massimo Bernardi, Andrés JM Ferreri
Expert Review of Hematology.2022; 15(1): 33. CrossRef
Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse
Peng Du, Hongyi Chen, Li Shen, Xiao Liu, Xuefan Wu, Lang Chen, Aihong Cao, Daoying Geng
Current Oncology.2022; 29(9): 6642. CrossRef
Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?
Shaani Singhal, Ellathios Antoniou, Edward Kwan, Gareth Gregory, Leon T. Lai
Journal of Clinical Neuroscience.2022; 106: 110. CrossRef
Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy
Nalee Kim, Do Hoon Lim, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
Journal of Neuro-Oncology.2021; 154(2): 207. CrossRef
Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art
Mengyao Wang, Ying Qu, Danrong Hu, Ting Niu, Zhiyong Qian
Journal of Biomedical Nanotechnology.2021; 17(8): 1459. CrossRef
Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma
Tae Hoon Lee, Joo Ho Lee, Ji Hyun Chang, Sung-Joon Ye, Tae Min Kim, Chul-Kee Park, Il Han Kim, Byoung Hyuck Kim, Chan Woo Wee
Radiation Oncology Journal.2020; 38(1): 35. CrossRef
Advances and challenges in the treatment of primary central nervous system lymphoma
Hua Yang, Yang Xun, Anping Yang, Fang Liu, Hua You
Journal of Cellular Physiology.2020; 235(12): 9143. CrossRef
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
Jun Su Park, Do Hoon Lim, Yong Chan Ahn, Won Park, Seok Jin Kim, Won Seog Kim, Kihyun Kim
Japanese Journal of Clinical Oncology.2017; 47(11): 995. CrossRef
Role of radiation therapy in primary central nervous system lymphoma
Hyeon Kang Koh, Il Han Kim, Tae Min Kim, Do Hoon Lim, Dongryul Oh, Jae Ho Cho, Woo-Chul Kim, Jin Hee Kim, Woong-Ki Chung, Bae-Kwon Jeong, Ki Mun Kang, Semie Hong, Chang-Ok Suh, In Ah Kim
Journal of Neuro-Oncology.2017; 135(3): 629. CrossRef

12,511 View
77 Download
10 Web of Science
9 Crossref

Early Postoperative Intraperitoneal Chemotherapy for Macroscopically Serosa-Invading Gastric Cancer Patients: Oh Kyoung Kwon, Ho Young Chung, Wansik Yu; Cancer Res Treat. 2014;46(3):270-279. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.270

Abstract PDF PubReader ePub

Purpose
Peritoneal recurrence is one of the most common patterns of recurrence after gastric cancer surgery and it has a poor prognosis despite all efforts. The aim of this study is to evaluate the prognostic impact of early postoperative intraperitoneal chemotherapy (EPIC) after surgery with curative intent for macroscopically serosa-invading gastric cancer patients. Materials and Methods The records of 245 patients under the age of 70 were reviewed. These patients were suffering from macroscopically seroa-invading gastric cancer and they underwent curative surgery from 1995 to 2004 at the Kyungpook National University Hospital, Daegu, Korea. The overall survival, gastric cancer-specific survival, complications, and patterns of recurrence were compared between the patients who were treated with EPIC and those who were not. Results EPIC was administered to 65 patients, and the remaining 180 patients did not receive this treatment. The 5-year overall and gastric cancer-specific survival rates for the EPIC group were 47.4% and 53.1%, respectively, and those for the non-EPIC group were 26.7% and 29.7%, respectively (p=0.012 for overall survival and p=0.011 for gastric cancer-specific survival). The rates of peritoneal recurrence for the EPIC group and the non-EPIC group were 18.5% and 32.2%, respectively (p=0.038). There were no significant differences in the morbidity or mortality between the two groups. Based on a multivariate analysis of the factors with prognostic significance in univariate analyses, EPIC, pathological lymph node metastasis, differentiation, and the extent of gastric resection were independent prognostic factors. Conclusion The use of EPIC to treat gastric cancer patients with macroscopic serosal invasions resulted in better survival rate by reducing the risk of peritoneal recurrence.

Citations

Citations to this article as recorded by

Role of locoregional therapy in gastric cancer with peritoneal metastasis
Ankur Tiwari, Katiuscha Merath, Sukeshi Patel Arora, Alexander Parikh, Mio Kitano, Colin M. Court
Surgical Oncology Insight.2024; 1(2): 100056. CrossRef
Exploring the Efficacy of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Gastric Cancer: Meta-analysis Based on Randomized Controlled Trials
Ying Chen, Yang Zhou, Huaping Xiong, Zhen Wei, Dong Zhang, Shoushan Li
Annals of Surgical Oncology.2024;[Epub] CrossRef
Intraperitoneal chemotherapy for primary gastric cancer
Mingchun Mu, Zhaolun Cai, Xueting Liu, Bo Zhang, Zhixin Chen, Jiankun Hu, Kun Yang
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef
Progress in the Treatment of Peritoneal Metastatic Cancer and the Application of Therapeutic Nanoagents
Wenjun Dai, Yidan Chen, Yunxin Xue, Mimi Wan, Chun Mao, Ke Zhang
ACS Applied Bio Materials.2023; 6(11): 4518. CrossRef
Risk Assessment and Preventive Treatment for Peritoneal Recurrence Following Radical Resection for Gastric Cancer
Lin Xiang, Shuai Jin, Peng Zheng, Ewetse Paul Maswikiti, Yang Yu, Lei Gao, Jing Zhang, Ying Zhang, Hao Chen
Frontiers in Oncology.2022;[Epub] CrossRef
No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer
Yun-Zi Wu, Ming Wu, Xiao-Hao Zheng, Bing-Zhi Wang, Li-Yan Xue, Shi-Kang Ding, Lin Yang, Jian-Song Ren, Yan-Tao Tian, Yi-Bin Xie
World Journal of Gastroenterology.2022; 28(38): 5589. CrossRef
Survey and literature review on the importance of peritoneal cytology in staging and treatment of gastric cancer: always wash it before you treat it
Mark C. Harris, Andrew J. Cockbain, Patrick W. McQuillan, Harsh A. Kanhere
ANZ Journal of Surgery.2021; 91(1-2): 13. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Intraperitoneal Chemotherapy Using Fluorouracil Implants Combined With Radical Resection and Postoperative Adjuvant Chemotherapy for Stage III Gastric Cancer: A Multi-Center, Randomized, Open-Label, Controlled Clinical Study
Yan Xu, Rupeng Zhang, Chunfeng Li, Zhe Sun, Jingyu Deng, Xiaona Wang, Xuewei Ding, Baogui Wang, Qiang Xue, Bin Ke, Hongjie Zhan, Ning Liu, Yong Liu, Xuejun Wang, Han Liang, Yingwei Xue, Huimian Xu
Frontiers in Oncology.2021;[Epub] CrossRef
Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol
Jessica L. Reid, Harsh A. Kanhere, Peter J. Hewett, Timothy J. Price, Guy J. Maddern, Markus I. Trochsler
Pleura and Peritoneum.2021; 6(4): 151. CrossRef
The use of intraperitoneal chemotherapy for gastric malignancies
Antonio Macrì, Federico Morabito
Expert Review of Anticancer Therapy.2019; 19(10): 879. CrossRef
Issues on peritoneal metastasis of gastric cancer: an update
Zhen Wang, Jun-qiang Chen, Jin-lu Liu, Lei Tian
World Journal of Surgical Oncology.2019;[Epub] CrossRef
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
Adriana C. Gamboa, Joshua H. Winer
Cancers.2019; 11(11): 1662. CrossRef
Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis
Daisuke Kobayashi, Yasuhiro Kodera
Gastric Cancer.2017; 20(S1): 111. CrossRef
Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice
Kurt Van der Speeten, Lieselotte Lemoine, Paul Sugarbaker
Pleura and Peritoneum.2017; 2(2): 63. CrossRef
Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma
Lieselotte Lemoine, Paul Sugarbaker, Kurt Van der Speeten
International Journal of Hyperthermia.2017; 33(5): 582. CrossRef

11,856 View
81 Download
18 Web of Science
16 Crossref

A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions: Tae-Yong Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Wonshik Han, Kyubo Kim, Eui Kyu Chie, In-Ae Park, Young Tae Kim, Dong-Young Noh, Sung Whan Ha, Yung-Jue Bang; Cancer Res Treat. 2014;46(3):280-287. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.280

Abstract PDF PubReader ePub

Purpose
A newly isolated mediastinal lymph node (LN) or a small pulmonary nodule, which appears during breast cancer surveillance, may pose a diagnostic dilemma with regard to malignancy. We conducted this study to determine which clinical factors were useful for the differentiation of malignant lesions from benign lesions under these circumstances. Materials and Methods We enrolled breast cancer patients who were presented with a new isolated mediastinal LN or small pulmonary nodule that arose during surveillance, and whose lesions were pathologically confirmed. Tissue diagnosis was made by mediastinoscopy, video-assisted thoracic surgery or thoracotomy. Results A total of 43 patients were enrolled (mediastinal LN, 13 patients; pulmonary nodule, 30 patients). Eighteen patients (41.9%) were pathologically confirmed to have a benign lesion (benign group), and 25 patients (58.1%) were confirmed to have malignant lesion (malignant group). Between the two groups, the initial tumor size (p=0.096) and N stage (p=0.749) were similar. Hormone receptor negativity was more prevalent in the malignant group (59.1% vs. 40.9%, p=0.048). The mean lesion size was larger in the malignant group than in the benign group (20.8 mm vs. 14.4 mm, p=0.024). Metastatic lesions had a significantly higher value of maximal standardized uptake (mSUV) than that of benign lesions (6.4 vs. 3.4, p=0.021). Conclusion Hormone receptor status, lesion size, and mSUV on positron emission tomography are helpful in the differentiation of malignant lesions from benign lesions in breast cancer patients who were presented with a new isolated mediastinal LN or small pulmonary nodule during surveillance.

Citations

Citations to this article as recorded by

Unusual metastases of breast cancer: a single-center retrospective study
Pınar ÖZDEMİR AKDUR, Nazan ÇİLEDAĞ
The European Research Journal.2023; 9(6): 1444. CrossRef
18Fluorodeoxyglucose‐positron emission tomography/computed tomography features of suspected solitary pulmonary lesions in breast cancer patients following previous curative treatment
Lei Zhu, Haiman Bian, Lieming Yang, Jianjing Liu, Wei Chen, Xiaofeng Li, Jian Wang, Xiuyu Song, Dong Dai, Zhaoxiang Ye, Wengui Xu, Xiaozhou Yu
Thoracic Cancer.2019; 10(5): 1086. CrossRef

12,705 View
60 Download
2 Web of Science
2 Crossref

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy: Yong Joo Hong, Hye-Suk Han, Yusook Jeong, Jiwon Jeong, Sung-Nam Lim, Hyung Jin Choi, Hyun-Jung Jeon, Tae-Keun Oh, Sang-Jeon Lee, Ki Hyeong Lee; Cancer Res Treat. 2014;46(3):288-296. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.288

Abstract PDF PubReader ePub

Purpose
Non-metastatic colorectal cancer patients with diabetes have poor overall survival than those without diabetes. However, the effect of hyperglycemia on survival after diagnosis of metastatic colorectal cancer (CRC) has not been assessed. Therefore, we assessed the impact of hyperglycemia on the survival and infection-related adverse events (AEs) in patients with metastatic CRC. Materials and Methods We reviewed the records of 206 patients with newly diagnosed metastatic CRC who were treated with palliative chemotherapy from March 2000 to December 2012 at Chungbuk National University Hospital. The mean glucose level of each patient was calculated using all available glucose results. Results The mean glucose levels ranged between 76.8 and 303.5 mg/dL, and patients were categorized into quartiles in accordance to their mean glucose level: group 1 (< 106.7 mg/dL), group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and 17.9 months, respectively; however, this difference was not statistically significant (p=0.643). Compared with patients in group 1, those in groups 2, 3, and 4 were at a higher risk of infection-related AEs, according to a multivariate analysis (p=0.002). Conclusion Hyperglycemia was not associated with shorter survival; however, it was associated with infection-related AEs in patients with newly diagnosed metastatic CRC receiving palliative chemotherapy.

Citations

Citations to this article as recorded by

Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework
Ihab Kandil, Erin Keely
Canadian Journal of Diabetes.2022; 46(7): 730. CrossRef
Association of Comorbid Diabetes With Clinical Outcomes and Healthcare Utilization in Colorectal Cancer Survivors
Susan Storey, Zuoyi Zhang, Xiao Luo, Diane Von Ah, Megan Metzger, Jie Zhang, Amrutha Jakka, Kun Huang
Oncology Nursing Forum.2021; 48(2): 195. CrossRef
The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression
Helga Schultz, Ulrik Pedersen-Bjergaard, Andreas Kryger Jensen, Svend Aage Engelholm, Peter Lommer Kristensen
Clinical and Translational Radiation Oncology.2018; 11: 19. CrossRef
Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities
Susan Storey, Diane Ah, Marilyn Hammer
Oncology Nursing Forum.2017; 44(4): E141. CrossRef
Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors
Roy E. Strowd, Mackenzie C. Cervenka, Bobbie J. Henry, Eric H. Kossoff, Adam L. Hartman, Jaishri O. Blakeley
Neuro-Oncology Practice.2015; 2(3): 127. CrossRef
The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors
Roy E. Strowd, Stuart A. Grossman
Current Treatment Options in Oncology.2015;[Epub] CrossRef

11,954 View
72 Download
7 Web of Science
6 Crossref

Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells: Qingli Li, Lunxu Liu, Qiuyang Zhang, Sen Liu, Dongxia Ge, Zongbing You; Cancer Res Treat. 2014;46(3):297-306. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.297

Abstract PDF PubReader ePub

Purpose
Interleukin-17 (IL-17) is a proinflammatory cytokine that plays important roles in inflammation, autoimmunity, and cancer. The purpose of this study was to determine if IL-17 indirectly regulates macrophage differentiation through up-regulation of cyclooxygenase-2 (COX-2) expression in the cancer cell lines. Materials and Methods Human cervical cancer HeLa, human lung cancer A549, and mouse prostate cancer Myc-CaP/CR cell lines were treated with recombinant IL-17; Western blot analysis, enzyme-linked immunosorbent assay, and quantitative real-time polymerase chain reaction analysis were utilized to examine the cellular responses. Results IL-17 up-regulated expression of COX-2 mRNA and protein in HeLa, A549, and Myc- CaP/CR cell lines. IL-17’s effects were mediated through nuclear factor-κB and ERK1/2 signaling pathways as the inhibitors of these pathways could inhibit IL-17- induced COX-2 expression. The conditional medium obtained from the cancer cells contained prostaglandin E2, the levels of which were increased by IL-17 treatment. When treated with the conditional medium, particularly with the IL-17-induced conditional medium, mouse RAW264.7 macrophages and human THP-1 monocytes expressed higher levels of IL-10 (a marker of M2 macrophages) than inducible nitric oxide synthase or tumor necrosis factor α (markers of M1 macrophages). In contrast, when RAW264.7 and THP-1 cells were treated directly with IL-17, expression of these marker genes was not markedly changed. Conclusion The results of this study suggest that IL-17 indirectly promotes M2 macrophage differentiation through stimulation of the COX-2/PGE2 pathway in the cancer cells, thus IL-17 plays an indirect role in regulating the tumor immune microenvironment.

Citations

Citations to this article as recorded by

Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME)
Mahvash Sadeghi, Sajad Dehnavi, Moosa Sharifat, Amir Mohammad Amiri, Ali Khodadadi
Heliyon.2024; 10(5): e27480. CrossRef
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response
Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, Chaorong Wu, Clinton Wu, Laura Huppert, Lauren S. Levine, Paula Sison, Katy K. Tsai, Melissa Chow, Jee Hye Kang, Jimmy Hwang, James C. Lee, Ariel Oglesby, Jessica Venegas, Ben J. Brintz, Aik Ch
BJC Reports.2024;[Epub] CrossRef
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer
Jingyuan Li, Jun Tan, Tao Wang, Shan Yu, Guangliang Guo, Kan Li, Le Yang, Bin Zeng, Xueying Mei, Siyong Gao, Xiaomei Lao, Sien Zhang, Guiqing Liao, Yujie Liang
Experimental Hematology & Oncology.2024;[Epub] CrossRef
Breast cancer colonization by Malassezia globosa accelerates tumor growth
Miao-Miao Liu, Hui-Hui Zhu, Jie Bai, Zi-Ye Tian, Yu-Jing Zhao, Teun Boekhout, Qi-Ming Wang, Jianping Xu
mBio.2024;[Epub] CrossRef
The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer
Eri Ishikawa, Takahiro Watanabe, Takako Kihara, Mamiko Kuroiwa, Miki Komatsu, Sayaka Urano, Masayuki Nagahashi, Seiichi Hirota, Yasuo Miyoshi
Breast Cancer Research and Treatment.2024;[Epub] CrossRef
Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2
Qingsheng Li, Kevin E. Goggin, SeonYeong Seo, Jonathan M. Warawa, Nejat K. Egilmez
Cancer Immunology, Immunotherapy.2023; 72(4): 1047. CrossRef
Candida albicans Promotes Oral Cancer via IL-17A/IL-17RA-Macrophage Axis
Xu Wang, Shuangshaung Wu, Wenjie Wu, Wenqing Zhang, Linman Li, Qian Liu, Zhimin Yan, Jianping Xu
mBio.2023;[Epub] CrossRef
Tumor Necrosis Factor-α Promotes the Tumorigenesis, Lymphangiogenesis, and Lymphatic Metastasis in Cervical Cancer via Activating VEGFC-Mediated AKT and ERK Pathways
Xiao Chen, Luping Lin, Qiaoling Wu, Sang Li, Huihui Wang, Yang Sun, Jinghua Pan
Mediators of Inflammation.2023; 2023: 1. CrossRef
Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC)
Nikhil Chandnani, Vedika Shrirang Choudhari, Rajat Talukdar, Sudeshna Rakshit, Geetha Shanmugam, Shiuli Guchait, Ishika Gupta, Melvin George, Koustav Sarkar
Medical Oncology.2023;[Epub] CrossRef
The role of IL-17 in lung cancer growth
Liping Liu, Renli Liu, Chaojie Wei, Dong Li, Xiuzhu Gao
Cytokine.2023; 169: 156265. CrossRef
IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment
Meiying Song, Jie Liang, Luoyang Wang, Wei Li, Suli Jiang, Shuo Xu, Lei Tang, Qiaochu Du, Guixian Liu, Haining Meng, Dongchang Zhai, Shangheng Shi, Yanyan Yang, Li Zhang, Bei Zhang
International Immunopharmacology.2023; 123: 110757. CrossRef
Effect of perioperative acupoint electrical stimulation on macrophages in mice under operative stress
Yinzhou Zhang, Junying Wei, Xinyuan Wu, Mengting Jiang, Wuhua Ma, Yuhui Li
Journal of Inflammation.2023;[Epub] CrossRef
Obesity-Modified CD4+ T-Cells Promote an Epithelial-Mesenchymal Transition Phenotype in Prostate Cancer Cells
Alejandra De Angulo, Peyton Travis, Gloria Cecilia Galvan, Christopher Jolly, Linda deGraffenried
Nutrition and Cancer.2022; 74(2): 650. CrossRef
Tumor immunotherapy: Mechanisms and clinical applications
Cheng Nong, Pengbo Guan, Li Li, Huiyuan Zhang, Hongbo Hu
MedComm – Oncology.2022;[Epub] CrossRef
Interleukin-17D promotes lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway
Zhenzhen Lin, Qiumin Huang, Junrong Liu, Hao Wang, Xuexi Zhang, Zhiyan Zhu, Wei Zhang, Yiliang Wei, Zhe Liu, Wei Du
Aging.2022; 14(15): 6149. CrossRef
Prostate Infiltration by Treg and Th17 Cells as an Immune Response to Propionibacterium acnes Infection in the Course of Benign Prostatic Hyperplasia and Prostate Cancer
Sebastian Radej, Monika Szewc, Ryszard Maciejewski
International Journal of Molecular Sciences.2022; 23(16): 8849. CrossRef
The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors
Hamidreza Zalpoor, Fatemeh Aziziyan, Mahsa Liaghat, Maryam Bakhtiyari, Abdullatif Akbari, Mohsen Nabi-Afjadi, Razieh Forghaniesfidvajani, Nima Rezaei
Cell Communication and Signaling.2022;[Epub] CrossRef
Analysis of peripheral inflammatory T cell subsets and their effector function in patients with Birdshot Retinochoroiditis
Janine Trombke, Lucie Loyal, Julian Braun, Uwe Pleyer, Andreas Thiel, Dominika Pohlmann
Scientific Reports.2021;[Epub] CrossRef
MicroRNA-146a limits tumorigenic inflammation in colorectal cancer
Lucien P. Garo, Amrendra K. Ajay, Mai Fujiwara, Galina Gabriely, Radhika Raheja, Chantal Kuhn, Brendan Kenyon, Nathaniel Skillin, Ryoko Kadowaki-Saga, Shrishti Saxena, Gopal Murugaiyan
Nature Communications.2021;[Epub] CrossRef
Molecular insights into phytochemicals‐driven break function in tumor microenvironment
Priyanshi Rana, Amarjeet Shrama, Chandi C. Mandal
Journal of Food Biochemistry.2021;[Epub] CrossRef
Assessment of the presence of interleukin 17+ macrophages and Th17 cells in situ in lip and oral tongue cancer
Thâmara Manoela Marinho Bezerra, Bárbara Vanessa de Brito Monteiro, Joabe dos Santos Pereira, Luiz Arthur Barbosa Silva, Cassiano Francisco Weege Nonaka, Éricka Janine Dantas da Silveira, Márcia Cristina da Costa Miguel
Human Immunology.2021; 82(12): 945. CrossRef
Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers
Tianhan Xu, Sihui Yu, Jiawen Zhang, Sufang Wu
Journal of Hematology & Oncology.2021;[Epub] CrossRef
Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development
Heiko Roedig, Roxana Damiescu, Jinyang Zeng-Brouwers, Iva Kutija, Jonel Trebicka, Malgorzata Wygrecka, Liliana Schaefer
Seminars in Cancer Biology.2020; 62: 31. CrossRef
IL-17A Modulates Peritoneal Macrophage Recruitment and M2 Polarization in Endometriosis
Jessica E. Miller, Soo Hyun Ahn, Ryan M. Marks, Stephany P. Monsanto, Asgerally T. Fazleabas, Madhuri Koti, Chandrakant Tayade
Frontiers in Immunology.2020;[Epub] CrossRef
Interferon-Gamma Stimulated Murine MacrophagesIn Vitro: Impact of Ionic Composition and Osmolarity and Therapeutic Implications
Joshua Erndt-Marino, Daniel J. Yeisley, Hongyu Chen, Michael Levin, David L. Kaplan, Mariah S. Hahn
Bioelectricity.2020; 2(1): 48. CrossRef
Pleiotropic Role and Bidirectional Immunomodulation of Innate Lymphoid Cells in Cancer
Zhengwen An, Fabian Flores-Borja, Sheeba Irshad, Jinhai Deng, Tony Ng
Frontiers in Immunology.2020;[Epub] CrossRef
CD4+ T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion
Sen Liu, Fengli Liu, Bing Zhang, Peng Yan, Brian G. Rowan, Asim B. Abdel‐Mageed, Chad Steele, S. Michal Jazwinski, Krzysztof Moroz, Elizabeth B. Norton, Alun Wang, Leann Myers, Oliver Sartor, Qiuyang Zhang
The Prostate.2020; 80(10): 764. CrossRef
Concanavalin-A stimulates IL-17 and nitric oxide production and induces macrophage polarization and resistance to Trypanosoma cruzi infection
Nágela Ghabdan Zanluqui, Maria Isabel Lovo-Martins, Aparecida Donizette Malvezi, Carolina Panis, Rosiane Valeriano da Silva, Vera Lucia Hideko Tatakihara, Ionice Felipe, Marli Cardoso Martins-Pinge, Pryscilla Fanini Wowk, Phileno Pinge-Filho
Life Sciences.2020; 258: 118137. CrossRef
ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages
Jinlong Yin, Sung Soo Kim, Eunji Choi, Young Taek Oh, Weiwei Lin, Tae-Hoon Kim, Jason K. Sa, Jun Hee Hong, Se Hwan Park, Hyung Joon Kwon, Xiong Jin, Yeonhee You, Ji Hye Kim, Hyunggee Kim, Jaekyoung Son, Jeongwu Lee, Do-Hyun Nam, Kui Son Choi, Bingyang Shi
Nature Communications.2020;[Epub] CrossRef
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells
Nicholas J. Monteleone, Carol S. Lutz
Oncotarget.2020; 11(26): 2464. CrossRef
Dietary Supplementation of Foxtail Millet Ameliorates Colitis-Associated Colorectal Cancer in Mice via Activation of Gut Receptors and Suppression of the STAT3 Pathway
Bowei Zhang, Yingchuan Xu, Shuang Liu, Huan Lv, Yaozhong Hu, Yaya Wang, Zhi Li, Jin Wang, Xuemeng Ji, Hui Ma, Xiaowen Wang, Shuo Wang
Nutrients.2020; 12(8): 2367. CrossRef
Cellular and Molecular Progression of Prostate Cancer: Models for Basic and Preclinical Research
Sirin Saranyutanon, Sachin Kumar Deshmukh, Santanu Dasgupta, Sachin Pai, Seema Singh, Ajay Pratap Singh
Cancers.2020; 12(9): 2651. CrossRef
Innate Lymphoid Cells in the Malignant Melanoma Microenvironment
Aintzane Apraiz, Aitor Benedicto, Joana Marquez, Andrea Agüera-Lorente, Aintzane Asumendi, Elvira Olaso, Beatriz Arteta
Cancers.2020; 12(11): 3177. CrossRef
Role of interleukin-17 in acute myocardial infarction
Mónica Daniela Mora-Ruíz, Francisco Blanco-Favela, Adriana Karina Chávez Rueda, María Victoria Legorreta-Haquet, Luis Chávez-Sánchez
Molecular Immunology.2019; 107: 71. CrossRef
The Formation and Therapeutic Update of Tumor-Associated Macrophages in Cervical Cancer
Qun Wang, Alexander Steger, Sven Mahner, Udo Jeschke, Helene Heidegger
International Journal of Molecular Sciences.2019; 20(13): 3310. CrossRef
IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathway
Ming Bai, Li Zhang, Bo Fu, Jiuxu Bai, Yingjie Zhang, Guangyan Cai, Xueyuan Bai, Zhe Feng, Shiren Sun, Xiangmei Chen
Kidney International.2018; 93(4): 814. CrossRef
Mucosa-associated invariant T cells in malignancies: a faithful friend or formidable foe?
S. M. Mansour Haeryfar, Christopher R. Shaler, Patrick T. Rudak
Cancer Immunology, Immunotherapy.2018; 67(12): 1885. CrossRef
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
Adriana Albini, Antonino Bruno, Douglas M. Noonan, Lorenzo Mortara
Frontiers in Immunology.2018;[Epub] CrossRef
Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation
Arum Park, Yunhee Lee, Mi Sun Kim, Young Ju Kang, Young-Jun Park, Haiyoung Jung, Tae-Don Kim, Hee Gu Lee, Inpyo Choi, Suk Ran Yoon
Frontiers in Immunology.2018;[Epub] CrossRef
β-Catenin Regulation in Sporadic Colorectal Carcinogenesis: Not as Simple as APC
Ernst Fredericks, Gill Dealtry, Saartjie Roux
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef
The promotion of tissue engineering blood vessel patency by CGS21680 through regulating pro‐inflammatory activities of endothelial progenitor cell
Wen Chen, Li Xiao, Jian Bai, Wen Zeng, Mingcan Yang, Bingyi Shi, Chuhong Zhu
Journal of Biomedical Materials Research Part A.2018; 106(10): 2634. CrossRef
ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate
Nádia Ghinelli Amôr, Carine Ervolino de Oliveira, Thaís Helena Gasparoto, Vanessa Garcia Vilas Boas, Graziela Perri, Ramon Kaneno, Vanessa Soares Lara, Gustavo Pompermaier Garlet, João Santana da Silva, Gislâine A. Martins, Cory Hogaboam, Karen A. Cavassa
Oncotarget.2018; 9(56): 30894. CrossRef
Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis
Xin Qian, Hankui Chen, Xiaofeng Wu, Ling Hu, Qi Huang, Yang Jin
Cytokine.2017; 89: 34. CrossRef
Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis
Dali Tong, Qiuli Liu, Gaolei Liu, Jing Xu, Weihua Lan, Yao Jiang, Hualiang Xiao, Dianzheng Zhang, Jun Jiang
Cancer Letters.2017; 389: 23. CrossRef
Inflammation-Related Pancreatic Carcinogenesis
Juan-juan Dai, Ming-jie Jiang, Xing-Peng Wang, Ling Tian
Pancreas.2017; 46(8): 973. CrossRef
The paradox of Th17 cell functions in tumor immunity
Zahra Asadzadeh, Hamed Mohammadi, Elham Safarzadeh, Maryam Hemmatzadeh, Ahmad Mahdian-shakib, Farhad Jadidi-Niaragh, Gholamreza Azizi, Behzad Baradaran
Cellular Immunology.2017; 322: 15. CrossRef
IL-33 Signaling Regulates Innate IL-17A and IL-22 Production via Suppression of Prostaglandin E2 during Lung Fungal Infection
Jaleesa M. Garth, Kristen M. Reeder, Matthew S. Godwin, Joseph J. Mackel, Chad W. Dunaway, Jonathan P. Blackburn, Chad Steele
The Journal of Immunology.2017; 199(6): 2140. CrossRef
Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression
Meiyu Peng, Qi Zhang, Yingnan Cheng, Shuyu Fu, Huipeng Yang, Xiangdong Guo, Jieyou Zhang, Lina Wang, Lijuan Zhang, Zhenyi Xue, Yan Li, Yurong Da, Zhi Yao, Liang Qiao, Rongxin Zhang
Oncotarget.2017; 8(59): 99693. CrossRef
Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
Zoila Lopez-Bujanda, Charles G Drake
Journal of Leukocyte Biology.2017; 102(2): 393. CrossRef
hnRNPA2/B1 activates cyclooxygenase‐2 and promotes tumor growth in human lung cancers
Yang Xuan, Jingshu Wang, Liying Ban, Jian-Jun Lu, Canhui Yi, Zhenglin Li, Wendan Yu, Mei Li, Tingting Xu, Wenjing Yang, Zhipeng Tang, Ranran Tang, Xiangsheng Xiao, Songshu Meng, Yiming Chen, Quentin Liu, Wenlin Huang, Wei Guo, Xiaonan Cui, Wuguo Deng
Molecular Oncology.2016; 10(4): 610. CrossRef
Culture supernatants of cervical cancer cells induce an M2 phenotypic profile in THP-1 macrophages
Eliza Julia Pedraza-Brindis, Karina Sánchez-Reyes, Georgina Hernández-Flores, Alejandro Bravo-Cuellar, Luis Felipe Jave-Suárez, Adriana Aguilar-Lemarroy, Paulina Gómez-Lomelí, Brenda Anahí López-López, Pablo Cesar Ortiz-Lazareno
Cellular Immunology.2016; 310: 42. CrossRef
15-Lipoxygenase metabolites of α-linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammasome
Naresh Kumar, Geetika Gupta, Kotha Anilkumar, Naireen Fatima, Roy Karnati, Gorla Venkateswara Reddy, Priyanka Voori Giri, Pallu Reddanna
Scientific Reports.2016;[Epub] CrossRef
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment
Fabian Flores-Borja, Sheeba Irshad, Peter Gordon, Felix Wong, Ibrahim Sheriff, Andrew Tutt, Tony Ng
Journal of Immunology Research.2016; 2016: 1. CrossRef
Phytomedicine—Modulating oxidative stress and the tumor microenvironment for cancer therapy
Yu-Ting Cheng, Chun-Chih Yang, Lie-Fen Shyur
Pharmacological Research.2016; 114: 128. CrossRef
The Role of Interleukin-17 in Lung Cancer
Feng Wu, Juanjuan Xu, Qi Huang, Jieli Han, Limin Duan, Jinshuo Fan, Zhilei Lv, Mengfei Guo, Guorong Hu, Lian Chen, Shuai Zhang, Xiaonan Tao, Wanli Ma, Yang Jin
Mediators of Inflammation.2016; 2016: 1. CrossRef
Calreticulin Promotes Proliferation and Migration But Inhibits Apoptosis in Schwann Cells
Gui Huang, Zhulei Sun, Jiang Wu, Shaofeng Shui, Xinwei Han, Dong Guo, Tengfei Li
Medical Science Monitor.2016; 22: 4516. CrossRef
The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers
Jonas Kuiper, Aniki Rothova, Joke de Boer, Timothy Radstake
Progress in Retinal and Eye Research.2015; 44: 99. CrossRef
Genetic basis of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs
Francisca Gómez, James R. Perkins, Elena García-Martín, Gabriela Canto, José A. Cornejo-García
Current Opinion in Allergy & Clinical Immunology.2015; 15(4): 285. CrossRef
CD4, IL-17, and COX-2 Are Associated With Subclinical Inflammation in Malar Melasma
Adriana Rodríguez-Arámbula, Bertha Torres-Álvarez, Diego Cortés-García, Cornelia Fuentes-Ahumada, Juan Pablo Castanedo-Cázares
The American Journal of Dermatopathology.2015; 37(10): 761. CrossRef
Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity
Bing Liu, Liyan Qu, Shigui Yan
Cancer Cell International.2015;[Epub] CrossRef
M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure
Jeffrey P. Moore, Antony Vinh, Kellie L. Tuck, Samy Sakkal, Shalini M. Krishnan, Christopher T. Chan, Maggie Lieu, Chrishan S. Samuel, Henry Diep, Barbara K. Kemp-Harper, Marianne Tare, Sharon D. Ricardo, Tomasz J. Guzik, Christopher G. Sobey, Grant R. Dr
American Journal of Physiology-Heart and Circulatory Physiology.2015; 309(5): H906. CrossRef
Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma
Muly Tham, Karen Khoo, Kim Pin Yeo, Masashi Kato, Amelle Prevost-Blondel, Veronique Angeli, Jean-Pierre Abastado
Oncotarget.2015; 6(26): 22857. CrossRef
Interleukin-17A Promotes Arginase-1 Production and 2,4-Dinitrochlorobenzene-Induced Acute Hyperinflammation in Human Papillomavirus E7 Oncoprotein-Expressing Skin
Le Son Tran, Deepak Mittal, Stephen R. Mattarollo, Ian H. Frazer
Journal of Innate Immunity.2015; 7(4): 392. CrossRef

17,299 View
215 Download
74 Web of Science
63 Crossref

Case Reports

Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein: Jung Min Ha, Eun Kim, Woo Joo Lee, Ji-Won Hwang, Sehyo Yune, Young Hyeh Ko, Joon Young Choi, Seok Jin Kim, Won Seog Kim; Cancer Res Treat. 2014;46(3):307-311. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.307

Abstract PDF PubReader ePub

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma. It usually presents with nonspecific symptoms, such as fever, rather than with overt lymphadenopathy. Reports of hypercalcemia, as the initial presentation of IVLBCL, are limited in the literature, despite it being a well-known complication of various solid cancers. We present a 68-year-old male with severe hypercalcemia and increased levels of serum parathyroid hormone-related protein. He was diagnosed with IVLBCL, involving the bone marrow and spleen, and was successfully treated with rituximab-containing chemotherapy. A few previous case reports have shown hypercalcemia in patients with IVLBCL. Much like our case, previous cases with hypercalcemia had advanced diseases, including bone marrow invasion. Although it was an extremely rare manifestation of IVLBCL, we suggest that IVLBCL should be a part of the differential diagnosis in patients with unexplained hypercalcemia. Therefore, an active work-up might be recommended, including positron emission tomography/ computed tomography scan and bone marrow examination, which may be useful for early diagnosis.

Citations

Citations to this article as recorded by

Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature
Yingying Han, Qingjiao Li, Dan Wang, Lushan Peng, Tao Huang, Chunlin Ou, Keda Yang, Junpu Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma
Chae Hong Lim, Sang Eun Yoon, Won Seog Kim, Kyung-Han Lee, Seok Jin Kim
Cancer Management and Research.2021; Volume 13: 7289. CrossRef
Missed diagnosis of lymphoma presenting with humoral hypercalcemia of malignancy due to cessation of oncological workup after negative computed tomography scans
Ellery Altshuler, Mahmoud Aryan, William King, Rolando Otero
BMJ Case Reports.2021; 14(12): e246669. CrossRef
The spectrum of lymphoproliferative disorders in endocrine organs: from histology to molecular genetics
Silvia Uccella, Francesca Magnoli, Cristina Amaglio, Fausto Sessa, Stefano La Rosa
Diagnostic Histopathology.2019; 25(5): 166. CrossRef
Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years
Kosei Matsue, Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Daisuke Miura, Kengo Takeuchi
British Journal of Haematology.2019; 187(3): 328. CrossRef
Klinische und pathologische Charakteristika intravaskulärer Lymphome
L. Abraham, H. Kreipe, P. Raab, K. Hussein
Der Pathologe.2018; 39(3): 242. CrossRef
Primary Bone Marrow B-Cell Lymphoma Undetected by Multiple Imaging Modalities That Initially Presented with Hypercalcemia
Jin Sae Yoo, Juwon Kim, Hyeong Ju Kwon, Jung Soo Lim
Case Reports in Endocrinology.2018; 2018: 1. CrossRef
Klinische und pathologische Charakteristika intravaskulärer Lymphome
Lara Abraham, Hans H. Kreipe, Peter Raab, Kais Hussein
Wiener klinisches Magazin.2018; 21(5): 206. CrossRef

12,234 View
67 Download
7 Web of Science
8 Crossref

Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission: Won Sup Lee, Ji-Hyen Hwang, Moon Jin Kim, Se-Il Go, Anna Lee, Haa-Na Song, Min Jeong Lee, Myung Hee Kang, Hoon-Gu Kim, Jeong-Hee Lee; Cancer Res Treat. 2014;46(3):312-316. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.312

Abstract PDF PubReader ePub

Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a distinctive cutaneous lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic T cells, similar to panniculitis. It is well-established that patients who are diagnosed with SPTL usually respond poorly to chemotherapy, showing fatal outcome. As a first line treatment for SPTL, anthracycline-based chemotherapy was most frequently used. For the treatment of SPTL, the efficacy of cyclosporine A has been recently reported in relapsed SPTL after anthracycline-based chemotherapy. However, it is still not clear whether cyclosporine A can be used as a first-line treatment against SPTL. Here, we report a case of SPTL, which achieved complete remission for nine years after first-line cyclosporine A therapy. This study suggests that cyclosporine A can induce a complete long-term remission as a first-line treatment.

Citations

Citations to this article as recorded by

The pathophysiology and current treatments for the subcutaneous panniculitis‐like T cell lymphoma: An updated review
En‐Cheng Lin, Jia‐Bin Liao, Yu‐Han Fang, Chien‐Hui Hong
Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 27. CrossRef
A retrospective study of 18 children with subcutaneous panniculitis-like T-cell lymphoma: multidrug combination chemotherapy or immunomodulatory therapy?
Yanlong Duan, Huixia Gao, Chunju Zhou, Ling Jin, Jing Yang, Shuang Huang, Meng Zhang, Yonghong Zhang, Tianyou Wang
Orphanet Journal of Rare Diseases.2022;[Epub] CrossRef
Case Report—Indurated Plaques and Recurrent Fevers in a 37-Year-Old Man: Answer
Elizabeth Dao, Alexandra Bourgeois, Pamela Martin
The American Journal of Dermatopathology.2021; 43(10): 754. CrossRef
Hemophagocytic Lymphohistiocytosis as the Initial Presentation of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Rare Case Responding to Cyclosporine A and Steroids
Caitlin Sullivan, Arya Loghmani, Katharine Thomas, Rachna Jetly-Shridhar, Rajasree Pia Chowdry
Journal of Investigative Medicine High Impact Case Reports.2020;[Epub] CrossRef
Rare Cutaneous T-Cell Lymphomas
Fabiana Damasco, Oleg E. Akilov
Hematology/Oncology Clinics of North America.2019; 33(1): 135. CrossRef
Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population
Ting-An Lin, Ching-Fen Yang, Yao-Chung Liu, Jin-Hwang Liu, Tzeon-jye Chiou, Liang-Tsai Hsiao, Hsiu-Ju Yen, Chia-Jen Liu, Hao-Yuan Wang, Po-Shen Ko, Sheng-Hsuan Chien, Jyh-Pyng Gau
International Journal of Hematology.2019; 109(2): 187. CrossRef
Successful treatment of a rare subcutaneous panniculitis‐like T‐cell lymphoma: An unusual case report and literature review
Liye Xu, Yuxuan Che, Xiaolei Ding, Jincheng Song, Xian Zhang, Xiuhua Sun
Dermatologic Therapy.2019;[Epub] CrossRef
British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018
J. Berth‐Jones, L.S. Exton, E. Ladoyanni, M.F. Mohd Mustapa, V.M. Tebbs, P.D. Yesudian, N.J. Levell, P.M. McHenry, T.A. Leslie, S. Wakelin, R.Y.P. Hunasehally, M. Cork, G.A. Johnston, N. Chiang, F.S. Worsnop, A. Salim, D. Buckley, G. Petrof, N. Callachand
British Journal of Dermatology.2019; 180(6): 1312. CrossRef
A Systematic Approach to the Cutaneous Lymphoid Infiltrates: A Clinical, Morphologic, and Immunophenotypic Evaluation
Alejandro A. Gru, Chauncey McHargue, Andrea L. Salavaggione
Archives of Pathology & Laboratory Medicine.2019; 143(8): 958. CrossRef
Hemophagocytic lymphohistiocytosis: A rare, potentially fatal complication in subcutaneous panniculitis like T cell lymphoma
ChandraSekhar Sirka, Swetalina Pradhan, Susama Patra, Somanath Padhi, SarojKumar DasMajumdar, Debjani Panda
Indian Journal of Dermatology, Venereology and Leprology.2019; 85(5): 481. CrossRef
Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
Pilvi Maliniemi, Kirsi Laukkanen, Liisa Väkevä, Katja Dettmer, Tuomas Lipsanen, Leila Jeskanen, Alban Bessede, Peter J. Oefner, Marshall E. Kadin, Annamari Ranki
OncoImmunology.2017; 6(3): e1273310. CrossRef
Uncommon Variants of T-Cell Lymphomas
Neha Mehta-Shah, Steven Horwitz
Hematology/Oncology Clinics of North America.2017; 31(2): 285. CrossRef
Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review
Chi-Ching Chen, Chieh-Lin Teng, Su-Peng Yeh
Annals of Hematology.2016; 95(5): 837. CrossRef
Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides
Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, Patricia L. Myskowski, Alison Moskowitz, Steven M. Horwitz
Current Hematologic Malignancy Reports.2016; 11(3): 224. CrossRef
Zebras and hen's teeth: recognition and management of rare T and NK lymphomas
Neha Mehta–Shah, Steven Horwitz
Hematology.2015; 2015(1): 545. CrossRef

11,311 View
90 Download
16 Web of Science
15 Crossref

Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer: Hye Sook Kim, Suk-young Lee, Sang Cheul Oh, Chul Won Choi, Jun Suk Kim, Jae Hong Seo; Cancer Res Treat. 2014;46(3):317-321. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.317

Abstract PDF PubReader ePub

Standard endocrine therapy and chemotherapy can induce long-term remission in breast cancer patients; however, breast cancer can recur at any site. Pulmonary nodules with lymphadenopathy in advanced cancer patients are likely to be assumed as metastases. A 44-year-old woman with a history of breast cancer was presented to our institution with abnormal findings on 18-fluorodeoxyglucose positron emission tomography imaging, which suggested lung metastasis. She had previously been diagnosed with breast cancer (T1N2M0, Stage IIIa, intraductal carcinoma, triple negative cancer). Histological analysis of the mediastinal lymph node biopsy demonstrated sarcoidosis, showing a chronic, non-caseating, granulomatous inflammation. Our case highlights the need for non-malignant diagnoses in those with prior malignancies, and the need for histological evaluations in the event of first recurrence following potentially curative therapy.

Citations

Citations to this article as recorded by

Endobronchial ultrasound-guided transbronchial needle aspiration facilitating diagnosis of sarcoidosis in a breast cancer patient with multiple lymphadenopathy: a case report
Yuka Oride, Yumiko Koi, Tatsunari Sasada, Keiko Kajitani, Masahiro Ohara, Tomohiro Kondo, Yutaka Daimaru, Shingo Kawamura
Journal of Medical Case Reports.2022;[Epub] CrossRef
Sarcoidosis or metastatic rectal cancer? Diligent diagnosis for optimal therapeutic management
Tanya Odisho, Sonal Kaushik, An King Ang
Current Problems in Cancer: Case Reports.2022; 8: 100187. CrossRef
Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature
Hendrik Eggers, Marcus Krüger, Katharina Stange, Danny Jonigk, Christian Biancosino, Thomas Rodt, Thomas Fühner, Tim Murray, Viktor Grünwald, Philipp Ivanyi
Oncology Research and Treatment.2019; 42(7-8): 382. CrossRef
Concurrent Diagnoses of Cutaneous Sarcoidosis and Recurrent Metastatic Breast Cancer: More than a Coincidental Occurrence?
Jacqueline Deen, Nick Mellick, Laura Wheller
Case Reports in Dermatological Medicine.2018; 2018: 1. CrossRef
18F-FLUOROESTRADIOL PET/CT IN DIFFERENTIAL DIAGNOSIS OF LUNG LESIONS IN BREAST CANCER PATIENTS: CASE REPORTS
N. В. Vikhrova, A. A. Odzharova, M. В. Dolgushin, D. I. Nevzorov
Siberian journal of oncology.2018; 17(5): 111. CrossRef
Coexistence of sarcoidosis and metastatic lesions: A diagnostic and therapeutic dilemma (Review)
Christoph Spiekermann, Meike Kuhlencord, Sebastian Huss, Claudia Rudack, Daniel Weiï¿½
Oncology Letters.2017;[Epub] CrossRef
Sarcoidosis Presenting with Multiple Lung Parenchymal Nodules
Hyung-Jun Kim, Jimyung Park, Jee Min Kim, Ye Jin Lee, Hye-Rin Kang, Chang-Hoon Lee
The Ewha Medical Journal.2016; 39(2): 61. CrossRef
Systemic sarcoidosis mimicking malignant metastatic disease
Irena Hammen, David Lee Sherson, Jesper Roemhild Davidsen
European Clinical Respiratory Journal.2015; 2(1): 26761. CrossRef
Baohuoside I Suppresses Invasion of Cervical and Breast Cancer Cells through the Downregulation of CXCR4 Chemokine Receptor Expression
Buyun Kim, Byoungduck Park
Biochemistry.2014; 53(48): 7562. CrossRef

15,063 View
109 Download
12 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Previous issues